<SEC-DOCUMENT>0001493152-23-031526.txt : 20230901
<SEC-HEADER>0001493152-23-031526.hdr.sgml : 20230901
<ACCEPTANCE-DATETIME>20230901172640
ACCESSION NUMBER:		0001493152-23-031526
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20230901
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230901
DATE AS OF CHANGE:		20230901

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enveric Biosciences, Inc.
		CENTRAL INDEX KEY:			0000890821
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				954484725
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38286
		FILM NUMBER:		231233477

	BUSINESS ADDRESS:	
		STREET 1:		4851 TAMIAMI TRAIL N, SUITE 200
		CITY:			NAPLES
		STATE:			FL
		ZIP:			34103
		BUSINESS PHONE:		239-302-1707

	MAIL ADDRESS:	
		STREET 1:		4851 TAMIAMI TRAIL N, SUITE 200
		CITY:			NAPLES
		STATE:			FL
		ZIP:			34103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMERI Holdings, Inc.
		DATE OF NAME CHANGE:	20150527

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SPATIALIZER AUDIO LABORATORIES INC
		DATE OF NAME CHANGE:	19950323
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:envb="http://enveric.com/20230901">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_039_envb_enveric.com_20230901 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20230901_20230901 -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0000890821 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2023-09-01" name="dei:EntityCentralIndexKey">0000890821</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-09-01" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="envb-20230901.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2023-09-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-01</xbrli:startDate>
        <xbrli:endDate>2023-09-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_902_edei--DocumentType_c20230901__20230901_z3s7PtZlSjMk"><ix:nonNumeric contextRef="AsOf2023-09-01" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--DocumentPeriodEndDate_c20230901__20230901_zDM7uTQ902Fc"><ix:nonNumeric contextRef="AsOf2023-09-01" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">September
1, 2023</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
of Report (Date of earliest event reported)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90A_edei--EntityRegistrantName_c20230901__20230901_z5a0JYrdjQ9c"><ix:nonNumeric contextRef="AsOf2023-09-01" name="dei:EntityRegistrantName">Enveric
Biosciences, Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityIncorporationStateCountryCode_c20230901__20230901_zXiEAFgp1eBi"><ix:nonNumeric contextRef="AsOf2023-09-01" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityFileNumber_c20230901__20230901_zd8ZtHPaYu78"><ix:nonNumeric contextRef="AsOf2023-09-01" name="dei:EntityFileNumber">001-38286</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityTaxIdentificationNumber_c20230901__20230901_zmkrqHlwEold"><ix:nonNumeric contextRef="AsOf2023-09-01" name="dei:EntityTaxIdentificationNumber">95-4484725</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
    or other jurisdiction</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
    incorporation)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Commission</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>File
    Number)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(I.R.S.
    Employer</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification
    No.)</b></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityAddressAddressLine1_c20230901__20230901_zDrkyI9xwUwc"><ix:nonNumeric contextRef="AsOf2023-09-01" name="dei:EntityAddressAddressLine1">Enveric
Biosciences, Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityAddressAddressLine2_c20230901__20230901_zBAjcYNAPOp5"><ix:nonNumeric contextRef="AsOf2023-09-01" name="dei:EntityAddressAddressLine2">4851
Tamiami Trail N</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressAddressLine3_c20230901__20230901_zflkspdAH9T1"><ix:nonNumeric contextRef="AsOf2023-09-01" name="dei:EntityAddressAddressLine3">Suite 200</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityAddressCityOrTown_c20230901__20230901_z2aznreQhCv9"><ix:nonNumeric contextRef="AsOf2023-09-01" name="dei:EntityAddressCityOrTown">Naples</ix:nonNumeric></span>,
<span id="xdx_90F_edei--EntityAddressStateOrProvince_c20230901__20230901_zlQYy5G12FK9"><ix:nonNumeric contextRef="AsOf2023-09-01" name="dei:EntityAddressStateOrProvince">FL</ix:nonNumeric></span> <span id="xdx_907_edei--EntityAddressPostalZipCode_c20230901__20230901_zycJvGFzoxue"><ix:nonNumeric contextRef="AsOf2023-09-01" name="dei:EntityAddressPostalZipCode">34103</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address
of principal executive offices) (Zip code)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registrant&#8217;s
telephone number, including area code: <span id="xdx_901_edei--CityAreaCode_c20230901__20230901_zGqYEnPYH7hb"><ix:nonNumeric contextRef="AsOf2023-09-01" name="dei:CityAreaCode">(239)</ix:nonNumeric></span> <span id="xdx_906_edei--LocalPhoneNumber_c20230901__20230901_zmW5dwpW69hf"><ix:nonNumeric contextRef="AsOf2023-09-01" name="dei:LocalPhoneNumber">302-1707</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N/A</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Former
name or former address, if changed since last report.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--WrittenCommunications_c20230901__20230901_z0YqugB0EMZj"><ix:nonNumeric contextRef="AsOf2023-09-01" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--SolicitingMaterial_c20230901__20230901_z5jblYSefT9f"><ix:nonNumeric contextRef="AsOf2023-09-01" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--PreCommencementTenderOffer_c20230901__20230901_zNynXP4CbBI6"><ix:nonNumeric contextRef="AsOf2023-09-01" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--PreCommencementIssuerTenderOffer_c20230901__20230901_zipTJYEL0lC9"><ix:nonNumeric contextRef="AsOf2023-09-01" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 35%; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 41%; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--Security12bTitle_c20230901__20230901_zRGgsv8E0K9e"><ix:nonNumeric contextRef="AsOf2023-09-01" name="dei:Security12bTitle">Common
    stock, par value $0.01 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--TradingSymbol_c20230901__20230901_zkiV6cwciM01"><ix:nonNumeric contextRef="AsOf2023-09-01" name="dei:TradingSymbol">ENVB</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--SecurityExchangeName_c20230901__20230901_z7hYTmwYWrg"><ix:nonNumeric contextRef="AsOf2023-09-01" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The
    Nasdaq Stock Market</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_90B_edei--EntityEmergingGrowthCompany_c20230901__20230901_zrNEINPV1IIg"><ix:nonNumeric contextRef="AsOf2023-09-01" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%">&#160;</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1.01 Entry into a Material Definitive Agreement.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>On
September 1, 2023, Enveric Biosciences, Inc. (the &#8220;Company&#8221;) entered into an Equity Distribution Agreement (the &#8220;Distribution
Agreement&#8221;), with Canaccord Genuity LLC (&#8220;Canaccord&#8221;), pursuant to which the Company may offer and sell from time to
time, through Canaccord as sales agent and/or principal, shares of common stock of the Company, par value $0.01 per share (the &#8220;Common
Stock&#8221;), having an aggregate offering price of up to $10.0 million. Due to the offering limitations applicable to the Company under
General Instruction I.B.6. of Form S-3 and the Company&#8217;s public float as of September 1, 2023 and in accordance with the terms
of the Distribution Agreement, the Company may offer Common Stock having an aggregate gross sales price of up to $2,392,514 pursuant
to the prospectus supplement dated September 1, 2023 (the &#8220;Prospectus Supplement&#8221;).</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Common Stock will be offered and sold pursuant to an existing shelf registration statement on Form S-3 (File No. 333-257690) filed by
the Company with the Securities and Exchange Commission (&#8220;SEC&#8221;), which was declared effective on July 9, 2021 by the SEC.
The Prospectus Supplement relating to the offer and sale of the Common Stock pursuant to the Distribution Agreement also has been filed
with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Subject
to the terms and conditions of the</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribution Agreement<span style="background-color: white">,
Canaccord may sell the Common Stock by any method permitted by law deemed to be an &#8220;at-the-market offering&#8221; as defined in
Rule 415(a)(4) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Canaccord will use commercially reasonable
efforts to sell the Common Stock from time to time, based upon instructions from the Company (including any price, time or size limits
or other customary parameters or conditions the Company may impose). The Company will pay Canaccord a commission equal to 3.0% of the
gross sales price of the Common Stock sold through Canaccord under the</span> Distribution Agreement <span style="background-color: white">and
has also agreed to reimburse Canaccord for certain expenses. <span style="color: #212529">The Company may also sell Common Stock to Canaccord
as principal for Canaccord&#8217;s own account at a price agreed upon at the time of sale. Any sale of Common Stock to Canaccord as principal
would be pursuant to the terms of a separate terms agreement between the Company and Canaccord.</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #212529; background-color: white">The
Distribution Agreement contains customary representations and warranties of the parties and indemnification and contribution provisions
under which the Company and Canaccord have agreed to indemnify each other against certain liabilities, including liabilities under the
Securities Act. The Company expects to use the net proceeds from any sales of Common Stock under the Distribution Agreement for</span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general corporate purposes, which may include funding research
and development, increasing working capital, reducing indebtedness, acquisitions or investments in businesses, products or technologies
that are complementary to their own, and capital expenditures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
foregoing description of the</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribution Agreement <span style="background-color: white">is
not complete and is qualified in its entirety by reference to the full text of the</span> Distribution Agreement<span style="background-color: white">,
a copy of which is filed herewith as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the legal opinion and consent of <span style="background-color: white">Dickinson Wright PLLC</span> relating to the legality
of the Common Stock that may be issued pursuant to the Distribution Agreement is attached as Exhibit 5.1 <span style="background-color: white">to
this Current Report on Form 8-K</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01 Financial Statements and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Exhibits</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt; width: 0.75in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex1-1.htm">Equity Distribution Agreement, dated as of September 1, 2023, by and between Enveric Biosciences, Inc. and Canaccord Genuity LLC</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex5-1.htm">Opinion of Dickinson Wright PLLC regarding legality of the Common Stock</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex5-1.htm">Consent of Dickinson Wright PLLC (included in Exhibit 5.1)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (formatted as Inline XBRL)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%">&#160;</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    September 1, 2023</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC
    BIOSCIENCES, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Joseph Tucker</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
    Tucker</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%">&#160;</td><td style="width: 33%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKgkAQRb/Afxj2OWo1ovIxqYgsRCJ6XXKKJd2R2dXqk/rLViUaBobh3nOvECOxpY0ukeGyylM4YVWXyiHkeENGc0XvSHb7GPzN8a6tY2Vc//7AhDyDnpmNw+XVC7211RaLGORiMg0n0RTkPJZLyA4i6PSEzE0XaJxWJShTQMZUs0an+D0knNSLDFXvvuqMbDWZGMKxHOQPRDKM4EitehI/LKRpIoJRP4HYMjV1V9NYRxWsS6x8lx3Q/wZfIeZJWQ== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ex1-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 1.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enveric
Biosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
Stock<BR>
(par value $0.01 per share)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$10,000,000</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EQUITY
DISTRIBUTION AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
1, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canaccord
Genuity LLC<BR>
99 High Street, 12<SUP>th</SUP> Floor<BR>
Boston, Massachusetts 02110</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
Biosciences, Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), confirms this agreement (this &ldquo;<B>Agreement</B>&rdquo;)
with Canaccord Genuity LLC (the &ldquo;<B>Manager</B>&rdquo;) as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
1: <U>Description of Shares</U>. The Company may, from time to time during the term of this Agreement, issue and sell through or to the
Manager, as sales agent and/or principal, common stock of the Company, par value $0.01 per share, having an aggregate offering price
of up to $10,000,000 (the &ldquo;<B>Shares</B>&rdquo;) on the terms and subject to the conditions set forth herein. The common stock,
par value $0.01 per share, of the Company to be outstanding after giving effect to the sales contemplated hereby are hereinafter referred
to as the &ldquo;<B>Common Shares.</B>&rdquo; The Company agrees that, whenever the Company determines to sell Shares directly to the
Manager as principal, it will enter into a separate agreement (each, a &ldquo;<B>Terms Agreement</B>&rdquo;), in form and substance mutually
satisfactory to the Company and the Manager, relating to such sale in accordance with Section 3 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has filed not earlier than three years prior to the date hereof (the &ldquo;<B>Execution Date</B>&rdquo;), in accordance with
the provisions of the Securities Act of 1933, as amended, and the rules and regulations thereunder (collectively, the &ldquo;<B>Act</B>&rdquo;),
with the Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;), a registration statement (File No. 333-257690) on
Form S-3, including a Base Prospectus (as defined below), which specifically relates to Shares which may be issued from time to time
by the Company, and which incorporates by reference documents that the Company has filed or will file in accordance with the provisions
of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (collectively, the &ldquo;<B>Exchange Act</B>&rdquo;).
The Company has prepared a Prospectus Supplement (as defined below) to the Base Prospectus which specifically relates to the Shares.
Except where the context otherwise requires, &ldquo;<B>Registration Statement</B>,&rdquo; as used herein, means the registration statement,
including the Base Prospectus, as amended at the time of such registration statement&rsquo;s effectiveness or deemed effectiveness for
purposes of Section 11 of the Act, as such section applies to the Manager, including (1) all documents filed as a part thereof or incorporated
or deemed to be incorporated by reference therein, and (2) any information contained or incorporated by reference in a prospectus filed
with the Commission pursuant to Rule 424(b) under the Act, to the extent such information is deemed, pursuant to Rule 430B or Rule 430C
under the Act, to be part of the registration statement at the time of such registration statement&rsquo;s effectiveness or deemed effectiveness
for purposes of Section 11 of the Act, as such section applies to the Manager. Except where the context otherwise requires, &ldquo;<B>Base
Prospectus</B>,&rdquo; as used herein, means the prospectus filed as part of the Registration Statement, together with any amendments
or supplements thereto as of the date of this Agreement. Except where the context otherwise requires, &ldquo;<B>Prospectus Supplement</B>,&rdquo;
as used herein, means the final prospectus supplement relating to the Shares, filed by the Company with the Commission pursuant to Rule
424(b) under the Act in connection with the offering of the Shares. Except where the context otherwise requires, &ldquo;<B>Prospectus</B>,&rdquo;
as used herein, means the Prospectus Supplement together with the Base Prospectus. &ldquo;<B>Permitted Free Writing Prospectuses</B>,&rdquo;
as used herein, means the documents listed on <U>Schedule A</U> hereto. Any reference herein to the Registration Statement, the Base
Prospectus, the Prospectus Supplement or the Prospectus shall be deemed to refer to and include the documents incorporated or deemed
to be incorporated by reference therein pursuant to Item 12 of Form S-3 under the Act as of the date of such document. Any reference
herein to the terms &ldquo;<B>amend</B>,&rdquo; &ldquo;<B>amendment</B>&rdquo; or &ldquo;<B>supplement</B>&rdquo; with respect to the
Registration Statement, the Base Prospectus, the Prospectus Supplement, the Prospectus or any Permitted Free Writing Prospectus shall
be deemed to refer to and include the filing on or after the initial effective date of the Registration Statement, or the date of the
Base Prospectus, the Prospectus Supplement, the Prospectus or any Permitted Free Writing Prospectus, as the case may be, of any document
with the Commission deemed to be incorporated by reference therein. For purposes of this Agreement, all references to the Registration
Statement, the Prospectus or to any amendment or supplement thereto shall be deemed to include any copy filed with the Commission pursuant
to the Electronic Data Gathering Analysis and Retrieval System. &ldquo;<B>Execution Time</B>&rdquo; shall mean the date and time that
this Agreement is executed and delivered by the parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
2: <U>Representations and Warranties of the Company</U>. The Company represents and warrants to, and agrees with, the Manager on and
as of (i) the Execution Time, (ii) each date on which the Company executes and delivers a Terms Agreement, (iii) the time of each sale
of Shares pursuant to this Agreement (each, a &ldquo;<B>Time of Sale</B>&rdquo;), (iv) each Settlement Date (as defined in Section 3(a)(iv))
and (v) each Bring-Down Delivery Date (as defined in Section 4(m)) (each such dated listed in (i) through (v), a &ldquo;<B>Representation
Date</B>&rdquo;), that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<I>Registration. </I>The Company satisfies the conditions for the use of Form S-3 in connection with the offer and sale of the Shares
as contemplated hereby; the Registration Statement has become effective. The Registration Statement, at the Execution Time, and, as then
amended, at each other Representation Date, and at all times during which a prospectus is required by the Act to be delivered (whether
physically deemed to be delivered pursuant to Rule 153 under the Act or through compliance with Rule 172 under the Act or any similar
rule) in connection with any offer or sale of Shares, meets the requirements set forth in Rule 415(a)(1)(x) under the Act. Copies of
the Registration Statement have been delivered by the Company to the Manager.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<I>No Stop Order. </I>No stop order suspending the effectiveness of the Registration Statement, any post-effective amendment thereto
or the Rule 462(b) Registration Statement, if any, is in effect, and no proceedings for such purpose are pending before or, to the knowledge
of the Company, threatened by the Commission. The Commission has not issued any order preventing or suspending the use of any Prospectus
Supplement or any Permitted Free Writing Prospectus and no proceeding for that purpose has been initiated or, to the knowledge of the
Company, is threatened by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<I>Registration Statement and Prospectus Conform to the Requirements of the Act</I>. At the Execution Time, the Registration Statement
conformed, and, as then amended or supplemented as of each other Representation Date will conform, in all material respects, to the applicable
requirements of the Act. When the Prospectus is first filed in accordance with Rule 424(b) under the Act and as of each Representation
Date, the Prospectus, as amended or supplemented, will conform, in all material respects, to the applicable requirements of the Act and,
except to the extent the Manager shall agree in writing to a modification, shall be in all substantive respects in the form furnished
to the Manager prior to the Execution Time or, to the extent not completed at the Execution Time, shall contain only such specific additional
information and other changes as the Company has advised the Manager, prior to the Execution Time, will be included or made therein.
The Company meets, and at the time the Registration Statement was originally declared effective the Company met, the applicable requirements
of Form S-3 under the Act. The aggregate market value of securities sold by or on behalf of the Company pursuant to General Instruction
I.B.6 of Form S-3 during the 12 month period immediately prior to, and including, the date of this Agreement is no more than one-third
of the aggregate market value of the voting and non-voting common equity held by nonaffiliates of the Company, as determined pursuant
to General Instruction I.B.6 of Form S-3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<I>Permitted Free Writing Prospectuses Conform to the Requirements of the Act. </I>Each Permitted Free Writing Prospectus, if any, conformed
or will conform in all material respects to the requirements of the Act on the date of first use, and the Company has complied with all
prospectus delivery and filing requirements applicable to each such Permitted Free Writing Prospectus pursuant to the Act. The Company
has not made any offer relating to the Shares that would constitute a Permitted Free Writing Prospectus without the prior written consent
of the Manager. The Company has retained, in accordance with the Act, all Permitted Free Writing Prospectuses, if any, that were not
required to be filed pursuant to the Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<I>No Material Misstatements or Omissions. </I>As of its effective date, the Registration Statement did not, and does not and will not,
as then amended or supplemented, as of each Representation Date, contain an untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary to make the statements therein not misleading; as of its date the Prospectus did not,
and does not and will not, as then amended or supplemented, as of each Representation Date, contain an untrue statement of a material
fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were
made, not misleading; each Permitted Free Writing Prospectus, if any, as of its date, did not include any untrue statement of a material
fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading; each Permitted Free Writing Prospectus, if any, does not conflict with the information contained in the
Registration Statement, and each such Permitted Free Writing Prospectus, as supplemented by and taken together with the Prospectus as
of its date, did not and will not include any untrue statement of a material fact or omit to state any material fact necessary in order
to make the statements therein, in the light of the circumstances under which they were made, not misleading; <I>provided</I>, <I>however</I>,
that the representations and warranties set forth in this Section 2(e) do not apply to statements in or omissions from the Registration
Statement, the Prospectus or any Permitted Free Writing Prospectus or any such amendment or supplement thereto in reliance upon and in
conformity with written information furnished to the Company by or on behalf of the Manager expressly for use therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<I>Formation and Qualification</I>. Each of the Company, Jay Pharma Inc., a company incorporated pursuant to the laws of the Province
of Ontario, Canada (&ldquo;<B>Jay Pharma</B>&rdquo;), 1306432 B.C. Ltd. (&ldquo;<B>HoldCo</B>&rdquo;), a company incorporated pursuant
to the laws of the Province of British Columbia, Enveric Biosciences Canada, Inc., a company incorporated pursuant to the laws of the
Province of British Columbia (&ldquo;<B>Enveric Canada</B>&rdquo;), MagicMed USA, Inc., a corporation organized under the laws of the
Commonwealth of Massachusetts (&ldquo;<B>MagicMed</B>&rdquo;), Akos Biosciences, Inc., a Delaware Corporation (&ldquo;<B>Akos</B>&rdquo;),
and Enveric Therapeutics Pty. Ltd., a proprietary limited company incorporated in Australia (&ldquo;<B>Enveric Australia</B>&rdquo; and,
together with the Company, Jay Pharma, HoldCo, Enveric Canada, MagicMed, and Akos, collectively the &ldquo;<B>Company Parties</B>&rdquo;,
or each individually a &ldquo;<B>Company Party</B>&rdquo;) has been duly organized and is validly existing and is in good standing as
a corporation under the laws of its jurisdiction of organization with full corporate power and authority to own or lease, as the case
may be, and operate its properties and conduct its business as described in the Prospectus. Each of the Company Parties is duly registered
or qualified to transact business as a foreign corporation and is in good standing in all jurisdictions in which the conduct of its business
requires such registration or qualification, all of such jurisdictions being listed on <U>Schedule C</U> hereto, except where the failure
to be so registered or qualified or to be in good standing would not have a material adverse effect on (i) the condition (financial or
otherwise), properties, assets, liabilities, results of operations, earnings, business or prospects of the Company Parties taken as a
whole, whether or not arising from transactions in the ordinary course of business (a &ldquo;<B>Material Adverse Effect</B>&rdquo;) or
(ii) the performance of this Agreement or the transactions contemplated by this Agreement. At the Execution Time, the Company does not
own or control, directly or indirectly, any corporation, association or other entity other than the subsidiaries listed in Exhibit 21
to the Company&rsquo;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<I>Power and Authority</I>. The Company has all requisite corporate power and authority to execute and deliver this Agreement and perform
its obligations hereunder. The Company has all requisite power and authority to issue, sell and deliver the Shares, in accordance with
and upon the terms and conditions set forth in the certificate of incorporation of the Company (the &ldquo;<B>Charter</B>&rdquo;). All
corporate action required to be taken by any of the Company Parties or any of their respective directors for the authorization, issuance,
sale and delivery of the Shares and the consummation of the transactions contemplated by this Agreement has been validly taken.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<I>Shares. </I>The Shares to be issued and sold by the Company hereunder have been duly authorized and, when issued and delivered and
paid for as provided herein, will be duly and validly issued in accordance with the Charter, and will be fully paid and nonassessable
and will conform in all material respects to the description of the Common Shares in the Registration Statement and the Prospectus; and
except as described in or expressly contemplated by the Registration Statement and the Prospectus, there are no outstanding rights (including,
without limitation, preemptive rights), warrants or options to acquire, or instruments convertible into or exchangeable for, any Common
Shares or other equity security in the Company, or any contract, commitment, agreement, understanding or arrangement of any kind relating
to the issuance of any equity security of the Company or any such convertible or exchangeable securities, rights, warrants or options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<I>Outstanding Company Stock. </I>As of the Execution Date, the issued and outstanding capital stock of the Company consists of 2,181,912
Common Shares. All such shares have been duly authorized and validly issued in accordance with the Charter, and have been fully paid
and are nonassessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<I>Authorization, Execution and Delivery of this Agreement</I>. This Agreement has been duly authorized, executed and delivered by the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<I>Restrictions on Company Parties&rsquo; Ownership of Securities</I>. Other than the Company&rsquo;s ownership of all of the capital
stock of (1) Jay Pharma (2) HoldCo (3) MagicMed and (4) Enveric Canada, none of the Company Parties own, directly or indirectly, any
equity or long-term debt securities of any corporation, partnership, limited liability company, joint venture, association or other entity
except as may be disclosed in the Registration Statement and Prospectus after the Execution Time and in accordance with this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<I>No Violation or Default. </I>No Company Party is (i) in violation of its charter or by-laws, articles or similar organizational documents&#894;
(ii) in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance
or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement
or instrument to which such Company Party is a party or by which such Company Party is bound or to which any of the property of any Company
Party is subject&#894; or (iii) in violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator
or governmental or regulatory authority applicable to such Company Party or any of its properties, except, in the case of clauses (ii)
and (iii) above, for any such default, prospective default or violation that would not, individually or in the aggregate, have a Material
Adverse Effect or materially impair the ability of the Company to consummate the transactions contemplated by this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<I>No Conflicts</I>. The execution, delivery and performance by the Company of this Agreement, the issuance and sale of the Shares, the
consummation by the Company of the transactions contemplated hereby, and the application of the proceeds as described under the caption
&ldquo;Use of Proceeds&rdquo; in the Prospectus will not (i) conflict with or result in a breach or violation of any of the terms or
provisions of, or constitute a default under, result in the termination, modification or acceleration of, or result in the creation or
imposition of any lien, charge or encumbrance upon any property or assets of any Company Party pursuant to any indenture, mortgage, deed
of trust, loan agreement or other agreement or instrument to which any Company Party is a party or by which any Company Party is bound
or to which any of the property of any Company Party is subject, (ii) result in any violation of the provisions of the charter or by-laws,
articles or similar organizational documents of any Company Party or (iii) result in the violation of any law or statute or any judgment,
order, rule or regulation of any court or arbitrator or governmental or regulatory authority applicable to such Company Party or any
of its properties, except, in the case of clauses (i) and (iii) above, for any such conflict, breach, violation or default that would
not, individually or in the aggregate, have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
<I>No Consents Required</I>. No consent, approval, authorization, order, license, registration or qualification of or with any court
or arbitrator or governmental or regulatory authority is required in connection with the issuance and sale of the Shares and the consummation
by the Company of the transactions contemplated hereby, except for (i) the registration of the Shares under the Act and the Exchange
Act, (ii) as may be required by the Financial Industry Regulatory Authority, Inc. (&ldquo;<B>FINRA</B>&rdquo;), (iii) under applicable
state or Canadian securities laws in connection with the purchase and distribution of the Shares by the Manager, (iv) consents, approvals,
authorizations, orders, licenses, registrations or qualifications that have been or, prior to the Execution Date, as applicable, will
be obtained, (v) consents, approvals, authorizations, orders, licenses, registrations or qualifications that, if not obtained, would
not have a Material Adverse Effect or materially impair the ability of the Company to consummate the transactions contemplated by this
Agreement, (vi) any listing applications and related consents or any notices required by The Nasdaq Stock Market (&ldquo;<B>Nasdaq</B>&rdquo;)
in the ordinary course of the offering of the Shares, (vii) filings with the Commission pursuant to Rule 424(b) under the Act or (viii)
filings with the Commission on Form 8-K or otherwise with respect to this Agreement or required to be made in connection with the transactions
contemplated hereby or the registration of the Shares under the Act or the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
<I>Legal Proceedings</I>. Except as described in the Registration Statement or the Prospectus, there are no legal, governmental or regulatory
investigations, actions, suits, inquiries or proceedings pending or, to the knowledge of the Company, threatened to which any Company
Party is or may be a party or to which any property of any Company Party is or may be the subject that, individually or in the aggregate,
if determined adversely to any Company Party, would reasonably be expected to have a Material Adverse Effect. There are no current or
pending legal, governmental or regulatory investigations, actions, suits, inquiries or proceedings that are required under the Act to
be described in the Registration Statement or the Prospectus that are not so described therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
<I>Independent Accountants</I>. Marcum LLP (the &ldquo;<B>Accountant</B>&rdquo;), which has audited certain financial statements of the
Company, is an independent registered public accounting firm with respect to each entity it has audited within the applicable rules and
regulations adopted by the Commission and the Public Company Accounting Oversight Board (United States) and as required by the Act. To
the Company&rsquo;s knowledge, the Accountant is not and was not, during the term of its engagement as the Company&rsquo;s independent
registered public accounting firm, in violation of the auditor independence requirements of the Sarbanes-Oxley Act of 2002 and the rules
and regulations promulgated in connection therewith (the &ldquo;<B>Sarbanes-Oxley Act</B>&rdquo;) with respect to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
<I>Title to Real and Personal Property</I>. Except as described in the Registration Statement and the Prospectus and except to the extent
that failure of the following to be true, individually or in the aggregate, would not have a Material Adverse Effect: the Company Parties
have indefeasible title to all real property and good title to all personal property described in the Registration Statement and the
Prospectus as being owned by any of them, free and clear of all liens, other than as do not materially interfere with the use of such
properties, taken as a whole, as they have been used in the past and are proposed to be used in the future as described in the Registration
Statement and the Prospectus&#894; and all the property described in the Registration Statement and the Prospectus as being held under
lease by the Company Parties are held thereby under valid, subsisting and enforceable leases, except to the extent the failure to so
hold does not materially interfere with the use of such properties, taken as a whole, as they have been used in the past and are proposed
to be used in the future as described in the Registration Statement and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
<I>Title to Intellectual Property</I>. To the Company&rsquo;s knowledge, each of the Company Parties owns, possesses, licenses or has
other rights to use or otherwise receive the benefit of all material foreign and domestic patents, patent applications, trade and service
marks, trade and service mark registrations, trade names, copyrights, licenses, know-how (including trade secrets and other unpatented
and/or unpatentable proprietary or confidential information, systems or procedures) (collectively, &ldquo;<B>Intellectual Property</B>&rdquo;)
necessary for the conduct of their respective businesses as conducted and proposed to be conducted as described in the Registration Statement
and the Prospectus, except to the extent the failure to own, possess, license or have other rights to use or otherwise receive the benefit
of such rights does not have a Material Adverse Effect. The Company Parties have not received any notice of any claim of infringement,
misappropriation or conflict with any such rights of others in connection with its patents, patent rights, licenses, inventions, trademarks,
service marks, trade names, copyrights and know-how, which would reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as disclosed in the Registration Statement and the Prospectus, (i) to the Company&rsquo;s knowledge, there are no rights of third parties
to any such Intellectual Property owned, possessed, licensed or otherwise held by the Company Parties; (ii) to the Company&rsquo;s knowledge,
there is no infringement by third parties of any such Intellectual Property; (iii) there is no pending or, to the Company&rsquo;s knowledge,
threatened action, suit, inquiry, proceeding or claim brought by others challenging any Company Party&rsquo;s rights in or to any such
Intellectual Property, and the Company is unaware of any facts which could form a reasonable basis for any such action, suit, inquiry,
proceeding or claim; (iv) there is no pending or, to the Company&rsquo;s knowledge, threatened action, suit, inquiry, proceeding or claim
brought by others challenging the validity or scope of any such Intellectual Property; (v) there is no pending or, to the Company&rsquo;s
knowledge, threatened action, suit, inquiry, proceeding or claim brought by others that any Company Party has infringed, misappropriated
or otherwise violated any patent, trademark, copyright, trade secret or other proprietary rights of others or would, upon further development
or commercialization of any product, product candidate or service described in the Registration Statement and the Prospectus as under
development, infringe, misappropriate or violate, any intellectual property of others, and the Company is unaware of any facts that would
form a basis for any such claim; (vi) to the Company&rsquo;s knowledge, there is no third-party U.S. patent or published U.S. patent
application which contains claims for which an Interference Proceeding (as defined in 35 U.S.C. &sect; 135) has been commenced against
any patent or patent application described in the Registration Statement and Prospectus as being owned by or licensed to the Company;
(vii) there is no prior act or public or commercial activity of which the Company is aware that would reasonably be expected to render
any patent included in the Intellectual Property invalid or that would preclude the issuance of any patent on any patent application
included in the Intellectual Property which has not been disclosed to the U.S. Patent and Trademark Office or the relevant foreign patent
authority, as the case may be; (viii) to the Company&rsquo;s knowledge, the Company has not committed any act or omitted to undertake
any act the effect of such commission or omission would reasonably be expected to result in a legal determination that any item of Intellectual
Property thereby was rendered invalid or unenforceable in whole or in part; (ix) to the Company&rsquo;s knowledge, the issued patents
included in the Intellectual Property are valid and enforceable and the Company is unaware of any facts that would preclude the issuance
of a valid and enforceable patent on any pending patent application included in the Intellectual Property; (x) the use or composition
of the product candidates described in the Registration Statement and the Prospectus as under development by the Company fall within
the scope of one or more claims of the patents or patent applications included in the Intellectual Property; (xi) the Company has taken
reasonable steps necessary to secure the interests of the Company in the Intellectual Property purported to be owned by the Company from
any employees, consultants, agents or contractors that developed (in whole or in part) such Intellectual Property; (xii) the Company
Parties have complied with the terms of each agreement pursuant to which Intellectual Property has been licensed to such Company Party,
and all such agreements are in full force and effect and, (xiii) to the Company&rsquo;s knowledge, regarding the Intellectual Property,
no employee of a Company Party is in or has ever been in violation of any term of any employment contract, patent disclosure agreement,
invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement or any restrictive covenant
to or with a former employer where the basis of such violation relates to such employee&rsquo;s employment with the Company Party or
actions undertaken by the employee while employed with the Company Party, except, in the case of any of clauses (i)-(xiii) above, for
any such rights of or infringement by third parties or any such pending or threatened suit, action, proceeding or claim, or any non-compliance,
act, event, occurrence, or fact as would not, individually or in the aggregate, result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
<I>Consents and Permits</I>. Except as disclosed in the Registration Statement and the Prospectus, the Company Parties have made all
filings, applications and submissions required by, possess and are operating in compliance with, all approvals, licenses, certificates,
certifications, clearances, consents, grants, exemptions, marks, notifications, orders, permits and other authorizations issued by the
appropriate Governmental Authority necessary for the ownership or lease of their respective properties or to conduct their businesses
as described in the Registration Statement and the Prospectus (collectively, &ldquo;<B>Permits</B>&rdquo;), except for such Permits the
failure of which to possess, obtain or make the same would not have a Material Adverse Effect; the Company Parties are in compliance
with the terms and conditions of all such Permits, except where the failure to be in compliance would not have a Material Adverse Effect;
all of the Permits are valid and in full force and effect, except where any invalidity, individually or in the aggregate, would not have
a Material Adverse Effect; and none of the Company Parties have received any written notice relating to the limitation, revocation, cancellation,
suspension, modification or non-renewal of any such Permit which, singly or in the aggregate, if the subject of an unfavorable decision,
ruling or finding, would have a Material Adverse Effect, or have any reason to believe that any such license, certificate, permit or
authorization will not be renewed in the ordinary course. &ldquo;<B>Governmental Authority</B>&rdquo; means (i) any federal, provincial,
state, local, municipal, national or international government or governmental authority, regulatory or administrative agency, governmental
commission, department, board, bureau, agency or instrumentality, court, tribunal, arbitrator or arbitral body (public or private) (including,
without limitation, the United States Food and Drug Administration (the &ldquo;<B>FDA</B>&rdquo;), Health Canada, and the Australian
Therapeutic Goods Administration (the &ldquo;<B>TGA</B>&rdquo;)); (ii) any self-regulatory organization; or (iii) any political subdivision
of any of the foregoing. To the extent required by applicable laws and regulations of the FDA, the applicable Company Party has submitted
to the FDA an Investigational New Drug Application or amendment or supplement thereto for each clinical trial it has conducted or sponsored
or is conducting or sponsoring; all such submissions were in material compliance with applicable laws and rules and regulations when
submitted and no material deficiencies have been asserted by the FDA with respect to any such submissions. The Company Parties possess
such valid and current certificates, authorizations or permits issued by the appropriate state, federal or foreign regulatory agencies
or bodies necessary to conduct their respective businesses, and none of the Company Parties has received any notice of proceedings relating
to the revocation or modification of, or non-compliance with, any such certificate, authorization or permit which, singly or in the aggregate,
if the subject of an unfavorable decision, ruling or finding, would result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
<I>Regulatory Filings</I>. Except as disclosed in the Registration Statement and the Prospectus, none of the Company Parties have failed
to file with the applicable Governmental Authorities (including, without limitation, the FDA, Health Canada, the TGA, or any foreign,
federal, state, provincial or local Governmental Authority performing functions similar to those performed by the FDA) any required filing,
declaration, listing, registration, report, document, form, notice, application, claim, submission, supplement or amendment, except for
such failures that, individually or in the aggregate, would not have a Material Adverse Effect; except as disclosed in the Registration
Statement and the Prospectus, all such filings, declarations, listings, registrations, reports, documents, forms, notices, applications,
claims, submissions, supplements or amendments were complete, correct and in compliance with applicable laws when filed (or were corrected
or supplemented by a subsequent submission) and no deficiencies have been asserted by any applicable governmental or regulatory authority
with respect to any such filings, declarations, listings, registrations, reports, documents, forms, notices, applications, claims, submissions,
supplements or amendments, except for any deficiencies that, individually or in the aggregate, would not have a Material Adverse Effect.
The Company Parties have operated and currently are, in all material respects, in compliance with the United States Federal Food, Drug,
and Cosmetic Act (the &ldquo;<B>FDCA</B>&rdquo;), the Canada Food and Drugs Act, the Australian Therapeutic Goods Act 1989 and Australia
New Zealand Food Standards Code, all applicable rules and regulations of the FDA, Health Canada, the TGA, and other federal, state, provincial,
local and foreign Governmental Authority exercising comparable authority, except where the failure to comply, individually or in the
aggregate, would not have a Material Adverse Effect. Except as disclosed in the Registration Statement and the Prospectus, none of the
Company Parties have (i) received any notice from any court or arbitrator or governmental or regulatory authority or third party alleging
or asserting noncompliance with any laws or any licenses, exemptions, certificates, approvals, clearances, authorizations, permits, registrations
and supplements or amendments thereto required to conduct the Company&rsquo;s business as presently conducted (the &ldquo;<B>Authorizations</B>&rdquo;)
or (ii) received any written notice that any court or arbitrator or governmental or regulatory authority has taken, is taking or intends
to take, action to limit, suspend, materially modify or revoke any Authorizations, nor is any such limitation, suspension, modification
or revocation threatened. The Company Parties possess, unless otherwise disclosed in the Registration Statement and the Prospectus, all
material Authorizations and such Authorizations are valid and in full force and effect and are not in violation of any term of any such
Authorizations. The Company Parties are not party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement
orders, or similar agreements with or imposed by any governmental or regulatory authority, except as otherwise described in this Section
2(u), such as could not have or reasonably be expected to result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)
<I>Health Care Authorizations</I>. The Company has submitted and possesses, or qualifies for applicable exemptions to, such valid and
current registrations, listings, approvals, licenses, certificates, authorizations or permits and supplements or amendments thereto (collectively,
&ldquo;<B>Health Care Authorizations</B>&rdquo;) issued or required by the appropriate local, state, federal, national, supranational
or other foreign regulatory agencies or bodies (collectively, &ldquo;<B>Health Regulatory Agencies</B>&rdquo;) necessary to conduct its
business as described in the reports, schedules, forms, statements and other documents filed with the Commission, including, without
limitation, all such Health Care Authorizations required by the FDA, the Drug Enforcement Administration as required for research involving
Schedule 1 controlled substances, the Department of Health and Human Services, the European Commission, the European Medicines Agency
(the &ldquo;<B>EMA</B>&rdquo;) or any other Health Regulatory Agencies as may be required. The information and data submitted on any
Health Care Authorization application or submission was true and complete in all material respects as of the date of submission. The
Company has not received any notice of proceedings, or have any knowledge of any threatened proceedings, relating to the revocation or
modification of, or non-compliance with, any such Health Care Authorization, except where such revocation, modification or non-compliance
would not result in a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
<I>Compliance with Healthcare Laws</I>. The Company is, and has been, in compliance with all applicable Health Care Laws, and has not
engaged in activities which are, as applicable, cause for false claims liability or civil penalties, except where such noncompliance,
false claims liability or civil penalties would not reasonably be expected to, singly or in the aggregate, result in a Material Adverse
Effect. For purposes of this Agreement, &ldquo;<B>Health Care Laws</B>&rdquo; means all health care laws applicable to the Company, including,
but not limited to: the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section 301 et seq.), the Anti-Kickback Statute (42 U.S.C. Section
1320a-7b(b)), the Civil Monetary Penalties Law (42 U.S.C. &sect; 1320a-7a), the Civil False Claims Act (31 U.S.C. Section 3729 et seq.),
the criminal False Claims Law (42 U.S.C. &sect; 1320a-7b(a)), all criminal laws relating to health care fraud and abuse, including but
not limited to 18 U.S.C. Sections 286 and 287, and the health care fraud criminal provisions under the U.S. Health Insurance Portability
and Accountability Act of 1996 (&ldquo;<B>HIPAA</B>&rdquo;) (42 U.S.C. Section 1320d et seq.), the exclusion laws (42 U.S.C. &sect; 1320a-7),
Basic Health and Human Services Policy for Protection of Human Research Subjects &ldquo;Common Rule&rdquo; as codified and enforced by
the Department of Health and Human Services in 45 C.F.R. part 46 and enforced by FDA under 21 C.F.R. part 50, Laboratory Animal Welfare
Act of 1966, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section 17921 et
seq.) any and all other applicable comparable local, state, federal, national, supranational and foreign health care laws and the regulations
promulgated pursuant to such laws, each as amended from time to time; for the avoidance of doubt, Health Care Laws excludes any U.S.
federal laws, statutes, codes, ordinances, decrees, rules or regulations which apply to the production, trafficking, distribution, processing,
extraction, sale and/or possession of cannabis, marijuana, psilocybin or related substances, products or synthetic compounds containing
or related to same, including, but not limited to, the prohibition on drug trafficking under 21 U.S.C. &sect;84l(a). The Company has
not received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action
from any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is
in material violation of any Health Care Laws, and, to the knowledge of the Company, no such claim, action, suit, proceeding, hearing,
enforcement, investigation, arbitration or other action is threatened. The Company has not received any written notice of adverse filing,
warning letter, untitled letter or other correspondence or notice from any Health Regulatory Agencies, or any court or arbitrator, alleging
or asserting material noncompliance with the Health Care Laws. The Company is not a party to and has no ongoing reporting obligations
pursuant to any corporate integrity agreements, deferred prosecution agreements, monitoring agreements, consent decrees, settlement orders,
plans of correction or similar agreements with or imposed by any governmental or regulatory authority. Additionally, neither the Company,
nor, to the knowledge of the Company, any of its employees, officers or directors has been excluded, suspended or debarred from participation
in any U.S. federal health care program or human research study or trial or, to the knowledge of the Company, is subject to a governmental
inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension or exclusion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)
<I>Research Studies and Trials</I>. The research studies and trials conducted by or, to the Company&rsquo;s knowledge, on behalf of,
or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement and Prospectus,
were, and, if still pending, are being conducted in all material respects in accordance with all of the Healthcare Authorizations, experimental
protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product
candidates comparable to those being developed by the Company Parties and all applicable statutes, laws, rules and regulations of the
FDA, National Institute of Health Department of Health and Human Services, the European Commission, the EMA and any other Health Regulatory
Agencies to which it is subject, including, without limitation, the FDCA and its implementing regulations at 21 C.F.R. Parts 50, 54,
56 and 312, and the Canada Food and Drugs Act; the descriptions of such studies, tests and trials, and the results thereof, contained
in the Registration Statement and Prospectus are accurate and complete in all material respects and do not contain any misstatement of
a material fact or omit to state a material fact necessary to make such statements not misleading; the Company is not aware of any tests,
studies or trials not described in the Registration Statement or Prospectus, the results of which reasonably call into question the results
of the tests, studies and trials described in the Registration Statement or Prospectus; and the Company has not received any written
notice or correspondence from the FDA, Health Canada or any foreign, state or local Governmental Authority exercising comparable authority
or any institutional review board or comparable authority requiring or threatening the termination, suspension, clinical hold or material
modification of any tests, research studies or trials conducted by or on behalf of, or sponsored by, the Company or in which the Company
has participated that are described in the Registration Statement or the Prospectus, and, to the Company&rsquo;s knowledge, there are
no reasonable grounds for the same. There has not been any violation of applicable law or regulation by the Company in any of its product
development efforts, submissions or reports to the FDA, the European Commission, the EMA or any other Health Regulatory Agency that could
reasonably be expected to require investigation, corrective action or result in enforcement action, except where such violation would
not, singly or in the aggregate, result in a Material Adverse Effect. The research studies and clinical trials of Company are being conducted
in an ethical and humane manner under state, national or supra-national applicable laws and such studies and the clinical trials are
conducted under the auspices of a neutral and independent Institutional Animal Care and Use Committee or Institutional Review Board and
applicable state, national, or supra national agencies responsible for oversight.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
<I>Health Care Products Purchase, Development and Manufacturing.</I> The development, purchasing and manufacture of the Company&rsquo;s
products and active pharmaceutical ingredients by or, to the knowledge of the Company, on behalf of the Company is being conducted in
compliance with all applicable Health Care Laws or other Health Regulatory Agencies. Except as disclosed in the Registration Statement
and the Prospectus, the Company has not had any manufacturing site (whether owned by the Company or, to the knowledge of the Company,
that of a third party manufacturer for the Company&rsquo;s products) subject to an FDA, European Commission, EMA, TGA or other Health
Regulatory Agency shutdown or import or export prohibition, nor received any FDA, European Commission, EMA or other Health Regulatory
Agency &ldquo;warning letters,&rdquo; or &ldquo;untitled letters&rdquo; alleging or asserting material noncompliance with any applicable
Health Care Laws, requests to make material changes to the Company&rsquo;s products, processes or operations, or similar correspondence
or notice from the FDA, the European Commission, the EMA or any other Health Regulatory Agency alleging or asserting material noncompliance
with any applicable Health Care Laws, other than those that have been satisfactorily addressed and/or closed with the FDA, the European
Commission, the EMA or other Health Regulatory Agency. To the knowledge of the Company, none of the FDA, the European Commission, the
EMA or any other Health Regulatory Agency is considering such action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)
<I>No Undisclosed Relationships</I>. No relationship, direct or indirect, exists between or among any Company Party, on the one hand,
and the directors, officers, equity holders, customers or suppliers of any Company Party, on the other, that is required by the Act to
be described in the Registration Statement and the Prospectus and that is not so described in such documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)
<I>Investment Company Act</I>. None of the Company Parties is now or, after giving effect to the offering and sale of the Shares and
the application of the proceeds thereof as described in the Registration Statement and the Prospectus, will be required to register as
an &ldquo;investment company&rdquo; or an entity &ldquo;controlled&rdquo; by an &ldquo;investment company&rdquo;, in each case within
the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder (collectively,
the &ldquo;<B>Investment Company Act</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)
<I>Taxes</I>. The Company Parties have paid all federal, provincial, state, local, foreign and franchise taxes and filed all federal,
provincial, state, local, foreign and franchise tax returns required to be paid or filed through the date hereof, except for (i) the
payment of any taxes (A) that are being contested in good faith and for which adequate reserves have been provided or (B) which, if not
paid, would not have, individually or in the aggregate, a Material Adverse Effect, and (ii) the filing of any tax returns as to which
the failure to file would not have, individually or in the aggregate, a Material Adverse Effect&#894; and except as otherwise disclosed
in the Registration Statement and the Prospectus, there is no tax deficiency that has been, or could reasonably be expected to be, asserted
against any Company Party or any of their respective properties, except as would not have, individually or in the aggregate, a Material
Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)
<I>No Labor Disputes</I>. No labor disturbance by or dispute with employees of any of the Company Parties exists or, to the knowledge
of the Company, is contemplated or threatened, and none of the Company Parties are aware of any existing or imminent labor disturbance
by, or dispute with, the employees of any of their principal suppliers, contractors or customers, except, in each case, as would not
have, individually or in the aggregate, a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)
<I>Compliance with and Liability under Environmental Laws</I>. Except as described in the Registration Statement and the Prospectus:
(i) the Company Parties (A) are, and at all prior times were, in compliance with any and all applicable federal, provincial, state, local
and foreign laws, rules, regulations, requirements, decisions and orders relating to the protection of human health or safety, the environment,
natural resources, hazardous or toxic substances or wastes, pollutants or contaminants (collectively, &ldquo;<B>Environmental Laws</B>&rdquo;),
(B) have received and are in compliance with all permits, licenses, certificates or other authorizations or approvals required of them
under applicable Environmental Laws to conduct their respective businesses, and (C) have not received notice of any actual or potential
liability under or relating to any Environmental Laws, including for the investigation or remediation of any disposal or release of hazardous
or toxic substances or wastes, pollutants or contaminants, and have no knowledge of any event or condition that would result in any such
notice, and (ii) there are no costs or liabilities associated with Environmental Laws of or relating to the Company Parties, except in
the case of each of (i) and (ii) above, for any such failure to comply, or failure to receive required permits, licenses or approvals,
or cost or liability, as would not, individually or in the aggregate, have a Material Adverse Effect. Except as described in the Registration
Statement and the Prospectus, (x) there are no proceedings that are pending, or that are known to be contemplated, against the Company
Parties under any Environmental Laws in which a governmental entity is also a party, other than such proceedings regarding which it is
reasonably believed no monetary sanctions of $100,000 or more will be imposed, (y) the Company Parties are not aware of any issues regarding
compliance with Environmental Laws, or liabilities or other obligations under Environmental Laws or concerning hazardous or toxic substances
or wastes, pollutants or contaminants, that could reasonably be expected to have a material effect on the capital expenditures or earnings
or financial position of the Company Parties, and (z) none of the Company Parties anticipates material capital expenditures relating
to any Environmental Laws. None of the Company Parties has been named as a &ldquo;potentially responsible party&rdquo; under the Comprehensive
Environmental Response, Compensation, and Liability Act of 1980, as amended, or any similar U.S. or non-U.S. state or local Environmental
Laws or regulation requiring such Company Party to investigate or remediate any pollutants or contaminants, except where such requirements
would not, individually or in the aggregate, have a Material Adverse Effect, whether or not arising from transactions in the ordinary
course of business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)
<I>Disclosure Controls</I>. The Company maintains effective &ldquo;disclosure controls and procedures&rdquo; (as defined in Rule 13a-15(e)
of the Exchange Act) which (i) are designed to ensure that material information relating to the Company Parties is made known to the
Company&rsquo;s principal executive officer and its principal financial officer by others within those entities, especially during the
periods in which the periodic reports required under the Exchange Act are being prepared, (ii) have been evaluated by management of the
Company for effectiveness as of the end of the Company&rsquo;s most recent fiscal quarter, and (iii) are effective in all material respects
to perform the functions for which they were established.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)
<I>Insurance</I>. The Company Parties have, or are entitled to the benefit of, insurance (including self-insurance) covering their respective
properties, operations, personnel and businesses, including business interruption insurance, which insurance is in amounts and insures
against such losses and risks as are reasonably adequate to protect the Company Parties and their respective businesses in a commercially
reasonable manner&#894; and no Company Party has received notice from any insurer or agent of such insurer that capital improvements
or other expenditures are required or necessary to be made in order to continue such insurance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)
<I>Internal Accounting Controls. </I>The Company maintains a system of &ldquo;internal control over financial reporting&rdquo; (as defined
in Rule 13a-15(f) of the Exchange Act) that complies with the requirements of the Exchange Act and has been designed by, or under the
supervision of, its principal executive and principal financial officers, or persons performing similar functions, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles (&ldquo;<B>GAAP</B>&rdquo;). The Company maintains internal accounting controls sufficient
to provide reasonable assurance that (i) transactions are executed in accordance with management&rsquo;s general or specific authorization&#894;
(ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability
for assets&#894; (iii) access to assets is permitted only in accordance with management&rsquo;s general or specific authorization&#894;
and (iv) the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement
fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&rsquo;s rules
and guidelines applicable thereto. The Company&rsquo;s internal accounting controls are effective and the Company is not aware of any
material weaknesses in the accounting controls of the Company. The Company&rsquo;s independent auditors and board of directors have been
advised of: (x) all &ldquo;material weaknesses&rdquo; and &ldquo;significant deficiencies&rdquo; (each, as defined in Rule 12b-2 of the
Exchange Act), if any, in the design or operation of internal controls which could adversely affect the Company&rsquo;s ability to record,
process, summarize and report financial data and (y) all fraud, if any, whether or not material, that involves management or other employees
who have a role in the Company&rsquo;s internal controls (whether or not remediated); all such material weaknesses and significant deficiencies,
if any, have been disclosed in the Registration Statement and the Prospectus in all material respects; and, since the date of the most
recent evaluation of such disclosure controls and procedures and internal controls, there have been no significant changes in internal
controls or in other factors that could significantly affect internal controls, including any corrective actions with regard to significant
deficiencies and material weaknesses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)
<I>Financial Information</I>. The consolidated historical financial statements, including the notes thereto, and schedules of the Company
Parties included or incorporated by reference in the Registration Statement and the Prospectus present fairly the financial condition,
results of operations and cash flows of the Company as of the dates and for the periods indicated, comply as to form with the applicable
accounting requirements of the Act and the Exchange Act and have been prepared in conformity with GAAP applied on a consistent basis
throughout the periods involved (except as otherwise noted therein). All non-GAAP financial information included or incorporated by reference
in the Registration Statement and the Prospectus complies with the requirements of Regulation G and Item 10 of Regulation S-K under the
Act; and, except as disclosed in the Registration Statement and the Prospectus, there are no material off-balance sheet arrangements
(as defined in Regulation S-K under the Act, Item 303(a)(4)(ii)) or any other relationships with unconsolidated entities or other persons,
that may have a material current or, to the Company&rsquo;s knowledge, material future effect on the Company&rsquo;s consolidated financial
condition, results of operations, liquidity, capital expenditures, capital resources or significant components of revenue or expenses.
No other financial statements or schedules are required to be included or incorporated by reference in the Registration Statement or
the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)
<I>No Unlawful Payments. </I>None of the Company Parties nor any director, officer or employee of any of the Company Parties nor, to
the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of any Company Party has (i) used
any Company Party funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity&#894;
(ii) made or taken an act in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment or benefit
to any foreign or domestic government official or employee, including of any government-owned or controlled entity or of a public international
organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party
official or candidate for political office; (iii) violated or is in violation of any provision of the Foreign Corrupt Practices Act of
1977, as amended, or any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials
in International Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom, or any other applicable
anti-bribery or anti-corruption law&#894; or (iv) made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe
or other unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper
payment or benefit. Each Company Party has instituted, maintains and enforces, and will continue to maintain and enforce, policies and
procedures designed to promote and ensure compliance with all such applicable anti-bribery and anti-corruption laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
<I>Compliance with Anti-Money Laundering Laws</I>. The operations of the Company Parties are and have been conducted at all times in
material compliance with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions
Reporting Act of 1970, as amended by the USA Patriot Act, the applicable money laundering statutes of all jurisdictions where any Company
Party conducts business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered
or enforced by any governmental agency (collectively, the &ldquo;<B>Anti-Money Laundering Laws</B>&rdquo;), and no action, suit, inquiry
or proceeding brought by or before any court or governmental agency, authority or body or any arbitrator involving any of the Company
Parties with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened&#894; the Company acknowledges
that, in accordance with the requirements of the USA Patriot Act, the Manager is required to obtain, verify and record information that
identifies its clients, including the Company, which information may include the name and address of its clients, as well as other information
that will allow the Manager to properly identify its clients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)
<I>No Conflicts with Sanctions Laws. </I>None of the Company Parties, nor any directors, officers or employees thereof, nor, to the knowledge
of the Company, any agent, affiliate or other person associated with or acting on behalf of any Company Party, is currently the subject
or the target of any sanctions administered or enforced by the U.S. government (including, without limitation, the Office of Foreign
Assets Control of the U.S. Department of the Treasury or the U.S. Department of State and including, without limitation, the designation
as a &ldquo;specially designated national&rdquo; or &ldquo;blocked person&rdquo;), the United Nations Security Council, the European
Union, His Majesty&rsquo;s Treasury or other relevant sanctions authority (collectively, &ldquo;<B>Sanctions</B>&rdquo;), nor are any
of the Company Parties located, organized or resident in a country or territory that is the subject or target of Sanctions, including,
without limitation, Crimea, the so-called Donetsk People&rsquo;s Republic and so-called Luhansk People&rsquo;s Republic regions of Ukraine,
Cuba, Iran, North Korea, and Syria (each, a &ldquo;<B>Sanctioned Country</B>&rdquo;)&#894; and the Company will not directly or indirectly
use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary,
joint venture partner or other person or entity (i) to fund or facilitate any activities of or business with any person that, at the
time of such funding or facilitation, is the subject or target of Sanctions, (ii) to fund or facilitate any activities of or business
in any Sanctioned Country or (iii) in any other manner that will result in a violation by any person (including any person participating
in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. For the past five (5) years, none of the Company
Parties have knowingly engaged in or are now knowingly engaged in any dealings or transactions with any person that at the time of the
dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country. None of the Company Parties nor,
to the knowledge of the Company, any director, officer, agent, employee or affiliate of a Company Party, is a person that is, or is 50%
or more owned or otherwise controlled by a person that is: (x) the subject of any Sanctions or (y) located, organized or resident in
a Sanctioned Country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)
<I>No Restrictions on Subsidiaries. </I>No direct or indirect subsidiary of the Company is prohibited or restricted, directly or indirectly,
under any agreement or other instrument to which it is a party or is subject, from paying any distributions or dividends to the Company,
from making any other distribution on such subsidiary&rsquo;s ownership interests, from repaying to the Company any loans or advances
to such subsidiary from the Company or from transferring any of such subsidiary&rsquo;s properties or assets to the Company or any other
subsidiary of the Company. Except as set forth in the Registration Statement and in the Prospectus, the Company owns, directly or indirectly,
all of the equity interests of the subsidiaries of the Company free and clear of any lien, charge, security interest, encumbrance, right
of first refusal or other restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)
<I>No Broker&rsquo;s Fees. </I>None of the Company Parties has incurred any liability, or is a party to any contract, agreement or understanding
with any person (other than this Agreement) that would give rise to a valid claim against such Company Party or the Manager, for a brokerage
commission, finder&rsquo;s fee or like payment in connection with the offering and sale of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)
<I>No Preferential Rights. </I>Except as set forth in the Registration Statement and the Prospectus, no person, as such term is defined
in Rule 1-02 of Regulation S-X promulgated under the Act (each, a &ldquo;<B>Person</B>&rdquo;), has (i) the right, contractual or otherwise,
to cause the Company to issue or sell to such Person any Common Shares or shares of any other capital stock or other securities of the
Company, (ii) any preemptive rights, resale rights, rights of first refusal, rights of co-sale, or any other rights (whether pursuant
to a &ldquo;poison pill&rdquo; provision or otherwise) to purchase any Common Shares or shares of any other capital stock or other securities
of the Company from the Company, (iii) the right to act as an underwriter to the Company in connection with the offer and sale of the
Shares, or (iv) the right to require the Company to register any securities for sale under the Act by reason of the filing of the Registration
Statement with the Commission or the issuance and sale of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)
<I>No Material Adverse Change</I>. Subsequent to the respective dates as of which information is given in the Registration Statement,
the Prospectus and the Permitted Free Writing Prospectuses, if any, (i) there has not been any change in the capital stock or long-term
debt of any Company Party, or any dividend or distribution of any kind declared, set aside for payment, paid or made by a Company Party
on any class of capital stock, or any Material Adverse Effect, or any development involving a prospective Material Adverse Effect, in
or affecting the business, properties, prospects, earnings, rights, assets, management, financial position, or results of operations
of the Company Parties taken as a whole; (ii) none of the Company Parties has entered into any transaction or agreement that is material
to the Company Parties taken as a whole or incurred any liability or obligation, direct or contingent, that is material to the Company
Parties taken as a whole; and (iii) none of the Company Parties has sustained any material loss or interference with its business from
fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance or dispute or any action,
order or decree of any court or arbitrator or governmental or regulatory authority, except in each case as otherwise disclosed in the
Registration Statement or Prospectus (including any document deemed incorporated by reference therein).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oo)
<I>No Stabilization. </I>The Company Parties and their respective directors, officers, affiliates and controlling persons have not taken,
directly or indirectly, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation
of the price of any security of the Company to facilitate the sale or resale of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(pp)
<I>Statistical and Market Data. </I>Nothing has come to the attention of the Company that has caused the Company to believe that the
statistical and market-related data included in or incorporated by reference into the Registration Statement and the Prospectus is not
based on or derived from sources that are reliable and accurate in all material respects and the Company has obtained the written consent
to the use of such data from such sources to the extent required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(qq)
<I>Sarbanes-Oxley Act. </I>The Company has taken all necessary action to ensure that, upon the filing of the Registration Statement,
the Company and, to the knowledge of the Company, any of the Company&rsquo;s directors or officers, in their capacities as such, were,
and as of each Representation Date were or will be, in compliance in all material respects with any applicable provision of the Sarbanes-Oxley
Act, including Section 402 thereof related to loans and Sections 302 and 906 thereof related to certifications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(rr)
<I>Status under the Act. </I>At the time of filing the Registration Statement and any post-effective amendment thereto, at the earliest
time thereafter that the Company or any offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) under the Act)
of the Shares and at the date hereof, the Company was not and is not an &ldquo;ineligible issuer,&rdquo; as defined in Rule 405 under
the Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ss)
<I>Listing of the Shares</I>. At the Time of Sale, the Company will have filed an application for listing of the Shares on Nasdaq. The
Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Common Shares under the
Exchange Act, delisting the Common Shares from Nasdaq, nor has the Company received any notification that the Commission or Nasdaq is
contemplating terminating such registration or listing. To the Company&rsquo;s knowledge, it is in compliance with all applicable listing
requirements of Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(tt)
<I>Description of Securities</I>. There are no statutes, regulations, contracts or other documents required to be described in the Registration
Statement or the Prospectus or to be filed as exhibits to the Registration Statement that have not been described or filed as required.
The Company has not distributed and, prior to the later to occur of each Settlement Date and completion of the distribution of the Shares,
will not distribute any offering material in connection with the offering or sale of the Shares other than the Registration Statement
and the Prospectus and any Permitted Free Writing Prospectus to which the Manager has consented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(uu)
<I>Certain Market Activities. </I>None of the Company Parties, nor any of their respective directors, officers or controlling persons
has taken, directly or indirectly, any action designed, or that has constituted or might reasonably be expected to cause or result in,
under the Exchange Act or otherwise, the stabilization or manipulation of the price of any security of the Company to facilitate the
sale or resale of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vv)
<I>Cybersecurity; Data Protection</I>. The Company Parties&rsquo; information technology assets and equipment, computers, systems, networks,
hardware, software, websites, applications, and databases (collectively, &ldquo;<B>IT Systems</B>&rdquo;) are adequate for, and operate
and perform in all material respects as required in connection with, the operation of the business of the Company Parties as currently
conducted, to the Company&rsquo;s knowledge free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware
and other corruptants. The Company Parties have implemented and maintained commercially reasonable controls, policies, procedures, and
safeguards designed to maintain and protect their material confidential information and the integrity, continuous operation, redundancy
and security of all IT Systems and data (including all personal, personally identifiable, sensitive, confidential or regulated data (&ldquo;<B>Personal
Data</B>&rdquo;)) used in connection with their respective businesses and to the Company&rsquo;s knowledge there have been no breaches,
violations, outages or unauthorized uses of or accesses to the same, except for those that have been remedied without material cost or
liability or the duty to notify any other person and those that would not, individually or in the aggregate, have a Material Adverse
Effect, nor any incidents under internal review or investigations relating to the same. The Company Parties are presently in material
compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental
or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal
Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ww)
<I>Projections and Forward-Looking Statements. </I>No projection or other forward-looking statement (within the meaning of Section 27A
of the Act and Section 21E of the Exchange Act) included in any of the Registration Statement and the Prospectus has been made or reaffirmed
without a reasonable basis after due consideration by the Company of the underlying assumptions, estimates and other applicable facts
and circumstances or has been disclosed other than in good faith. No such statement was made with the knowledge of an executive officer
or director of the Company that was false or misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
3: <U>Sale and Delivery of Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
On the basis of the representations, warranties and agreements herein contained, and subject to the terms and conditions herein set forth,
the Company agrees to issue and sell through or to the Manager, as sales agent and/or principal, as and when it provides instructions,
in its discretion, for the sale of the Shares, and the Manager agrees to use its commercially reasonable efforts, consistent with its
normal trading and sales practices and applicable law and regulations, to sell, as sales agent for the Company, the Shares on the following
terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The Shares are to be sold by the Manager on a daily basis or otherwise as shall be mutually agreed upon by the Company and the Manager
on any trading day for Nasdaq (other than a day on which Nasdaq is scheduled to close prior to its regular weekday closing time) (each,
a &ldquo;<B>Trading Day</B>&rdquo;), for which (A) the Company, through any of the individuals listed as authorized representatives of
the Company on <U>Schedule B</U> hereto, as such <U>Schedule B</U> may be amended from time to time (the &ldquo;<B>Authorized Company
Representatives</B>&rdquo;), has instructed the Manager by telephone (confirmed promptly by electronic mail containing a notice substantially
in the form attached hereto as Exhibit 3(a)(i), with a copy to each of the other Authorized Company Representatives at such time) to
make such sales and (B) the Company has satisfied its obligations under Sections 4, 5 and 6 hereof. On or before a Trading Day that the
Company wishes to sell the Shares, the Company will designate in a notice delivered by electronic mail substantially in the form attached
hereto as Exhibit 3(a)(i) the maximum amount of the Shares to be sold by the Manager daily or over a specific trading period as agreed
to by the Manager (in any event not in excess of the amount available for issuance under the Prospectus and the Registration Statement
(including any limit set forth in General Instruction I.B.6 thereof, if applicable) or in an amount, together with all sales of the Shares
under this Agreement, in excess of the amount of Shares authorized from time to time to be issued and sold under this Agreement or below
any minimum price below which sales of the Shares may not be effected) and any other limitations specified by the Company and mutually
agreed by the Manager. For the avoidance of doubt, the foregoing limitation shall not apply to sales solely to employees or other security
holders of the Company or the Company Parties or to a trustee or other person acquiring the Shares for the accounts of such persons in
which the Manager is acting for the Company in a capacity other than as Manager under this Agreement. Subject to the terms and conditions
of this Section 3(a), the Manager may sell the Shares by any method permitted by law deemed to be an At the Market Offering (as defined
below), including, without limitation, sales made by means of ordinary brokers&rsquo; transactions, to or through a market maker at market
prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices (such transactions are hereinafter
referred to as &ldquo;<B>At the Market Offerings</B>&rdquo;). Subject to the terms and conditions of this Section 3(a) and the other
terms and conditions specified herein (including, without limitation, the accuracy of the representations and warranties of the Company
Parties and the performance by the Company of its covenants and other obligations, contained herein and the satisfaction of the additional
conditions specified in Section 6 hereof), the Manager shall use its commercially reasonable efforts to offer and sell all of the Shares
designated; <I>provided</I>, <I>however</I>, that the Manager shall have no obligation to offer or sell any Shares, and the Company acknowledges
and agrees that the Manager shall have no such obligation, in the event that an offer or sale of the Shares on behalf of the Company
may, in the reasonable judgment of the Manager, constitute the sale of a &ldquo;<B>block</B>&rdquo; under Rule 10b-18(a)(5) under the
Exchange Act or a &ldquo;<B>distribution</B>&rdquo; within the meaning of Rule 100 of Regulation M under the Exchange Act, or the Manager
reasonably believes that it may be deemed to be an &ldquo;<B>underwriter</B>&rdquo; under the Act in a transaction that is other than
by means of ordinary brokers&rsquo; transactions between members of Nasdaq that qualify for delivery of a Prospectus to Nasdaq in accordance
with Rule 153 under the Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Notwithstanding the foregoing, the Company, through any of the Authorized Company Representatives, may instruct the Manager by telephone
(confirmed promptly by electronic mail) not to sell the Shares if such sales cannot be effected at or above the price designated by the
Company in any such instruction. In addition, the Company or Manager may, upon notice to the other party hereto by telephone (confirmed
promptly by electronic mail), suspend the offering of the Shares for a specified period (a &ldquo;<B>Suspension Period</B>&rdquo;); <I>provided</I>,
<I>however</I>, that such Suspension Period shall not affect or impair the parties&rsquo; respective obligations with respect to the
Shares sold hereunder prior to the giving of such notice and <I>provided</I>, <I>further</I>, that there shall be no obligations under
Sections 4(m), 4(n), 4(p) and 4(q) with respect to the delivery of certificates, opinions, or comfort letters to the Manager during a
Suspension Period and that such obligations shall recommence on the termination of the Suspension Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
The Manager hereby covenants and agrees not to make any sales of the Shares on behalf of the Company, pursuant to this Section 3(a),
other than (A) by means of At the Market Offerings and (B) such other sales of the Shares on behalf of the Company in its capacity as
agent of the Company as shall be mutually agreed upon by the Company and the Manager.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
The compensation to the Manager, as an agent of the Company, for sales of the Shares shall be 3.0% of the gross sales price of the Shares
sold pursuant to this Section 3(a). The remaining proceeds, after further deduction for any transaction fees imposed by any governmental
or self-regulatory organization in respect of such sales, shall constitute the net proceeds to the Company for such Shares (the &ldquo;<B>Net
Proceeds</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
If acting as sales agent hereunder, the Manager shall provide written confirmation to the Company (which may be by electronic mail) as
soon as is reasonably practicable following the close of trading on Nasdaq each day in which the Shares are sold pursuant to this Section
3(a) setting forth (i) the number of Shares sold on such day, (ii) the Net Proceeds to the Company, and (iii) the compensation payable
by the Company to the Manager with respect to such sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
Settlement for sales of the Shares pursuant to this Section 3(a) will occur on the second business day that is also a trading day on
Nasdaq following the date on which such sales are made (each such date, a &ldquo;<B>Settlement Date</B>&rdquo;). On each Settlement Date,
the Shares sold through the Manager for settlement on such date shall be issued and delivered by the Company to the Manager against payment
of the Net Proceeds for the sale of such Shares. Settlement for all such Shares shall be effected by free delivery of the Shares by the
Company or its transfer agent to the Manager&rsquo;s account, or to the account of the Manager&rsquo;s designee, at The Depository Trust
Company through its Deposit and Withdrawal at Custodian System (&ldquo;<B>DTC</B>&rdquo;) or by such other means of delivery as may be
mutually agreed upon by the parties hereto, which in all cases shall be freely tradable, transferable, registered shares in good deliverable
form, in return for payments in same day funds delivered to the account designated by the Company. If the Company, or its transfer agent
(if applicable), shall default upon its obligation to deliver the Shares on any Settlement Date, in addition to and in no way limiting
the rights and obligations set forth in Section 7(a) hereof, the Company shall (A) indemnify and hold the Manager harmless against any
loss, claim or damage arising from or as a result of such default by the Company and (B) pay the Manager any commission to which it would
otherwise be entitled absent such default. The Authorized Company Representatives shall be the contact persons for the Company for all
matters related to the settlement of the transfer of the Shares through DTC for purposes of this Section 3(a)(vi).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
At each Representation Date, the Company shall be deemed to have affirmed each representation and warranty contained in this Agreement.
Any obligation of the Manager to use its commercially reasonable efforts to sell the Shares on behalf of the Company shall be subject
to the continuing accuracy of the representations and warranties of the Company herein, to the performance by the Company of its obligations
hereunder and to the continuing satisfaction of the additional conditions specified in Section 6 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
If the Company wishes to issue and sell the Shares other than as set forth in Section 3(a) hereof, it will notify the Manager of the
proposed terms of such issuance and sale (each, a &ldquo;<B>Placement</B>&rdquo;). If the Manager, acting as principal, wishes to accept
such proposed terms (which it may decline to do for any reason in its sole discretion) or, following discussions with the Company, wishes
to accept amended terms, the Company and the Manager will enter into a Terms Agreement setting forth the terms of such Placement. In
the event of a conflict between the terms of this Agreement and the terms of any Terms Agreement, the terms of such Terms Agreement will
control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Under no circumstances shall the aggregate gross sales proceeds of the Shares sold pursuant to this Agreement exceed the lesser of (A)
the amount set forth in Section 1 hereof and (B) the amount available for offer and sale under the Registration Statement (including
any limit set forth in General Instruction I.B.6 thereof, if applicable), nor shall the aggregate amount of Shares sold pursuant to this
Agreement exceed the amount of Shares authorized to be issued and sold from time to time under this Agreement by the board of directors
of the Company, or a duly authorized committee thereof, and notified to the Manager in writing. The Manager shall have no responsibility
for maintaining records with respect to Shares available for sale under the Registration Statement or for determining the aggregate gross
sales price, number or minimum price of Shares duly authorized by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Each sale of the Shares through or to the Manager shall be made in accordance with the terms of this Agreement or, if applicable, a Terms
Agreement. The Manager&rsquo;s commitment, if any, to purchase Shares from the Company as principal shall be deemed to have been made
on the basis of the accuracy of the representations and warranties of the Company, and performance by the Company of its covenants and
other obligations, herein contained and shall be subject to the terms and conditions herein set forth. At the time of each Terms Agreement,
the Manager shall specify the requirements, if any, for the officers&rsquo; certificates, legal opinions and comfort letters pursuant
to Sections 4(m), 4(n), 4(p) and 4(q) hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Subject to the limitations set forth herein and as may be mutually agreed upon by the Company and the Manager, sales effected pursuant
to this Agreement may not be requested by the Company and need not be made by the Manager (i) at any time from and including the day
on which the Company shall issue a press release containing, or shall otherwise publicly announce, its earnings, revenues or other results
of operations (each, an &ldquo;<B>Earnings Announcement</B>&rdquo;) through and including the applicable Bring-Down Delivery Date of
the Company referenced in Section 4(q) below, or (ii) during any other period in which the Company is, or could be deemed to be, in possession
of material non-public information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
The Company acknowledges and agrees that (i) there can be no assurance that the Manager will be successful in selling the Shares, (ii)
the Manager will not incur liability or obligation to the Company or any other person or entity if it does not sell Shares for any reason
other than a failure by the Manager to use its commercially reasonable efforts consistent with its normal trading and sales practices
and applicable law and regulations to sell such Shares in accordance with the terms of this Agreement, and (iii) the Manager shall not
be under any obligation to purchase Shares on a principal basis pursuant to this Agreement except as otherwise specifically agreed by
the Manager and the Company pursuant to a Terms Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
4: <U>Covenants of the Company</U>. The Company agrees with the Manager:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
During the period in which a prospectus relating to the Shares is required to be delivered under the Act (whether physically, deemed
to be delivered pursuant to Rule 153 or through compliance with Rule 172 under the Act or any similar rule), to notify the Manager promptly
of the time when any amendment to the Registration Statement has become effective or any amendment or supplement to the Prospectus has
been filed; to prepare and file with the Commission, promptly upon the Manager&rsquo;s request, any amendments or supplements to the
Registration Statement or the Prospectus that, in the Manager&rsquo;s reasonable opinion, may be necessary or advisable in connection
with the offer of the Shares by the Manager; and to cause each amendment or supplement to the Prospectus to be filed with the Commission
as required pursuant to the applicable paragraph of Rule 424(b) of the Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
To promptly advise the Manager, confirming such advice in writing (which may be made by electronic mail), of any request by the Commission
for amendments or supplements to the Registration Statement, the Base Prospectus or the Prospectus or for additional information with
respect thereto, or of notice of examination, institution of proceedings for, or the entry of a stop order suspending the effectiveness
of the Registration Statement and, if the Commission should enter a stop order suspending the effectiveness of the Registration Statement,
to use its commercially reasonable efforts to obtain the lifting or removal of such order as soon as possible; to promptly advise the
Manager of any proposal to amend or supplement the Registration Statement, the Base Prospectus or the Prospectus, and to provide the
Manager and counsel for the Manager copies of any such documents (excluding any documents incorporated or deemed incorporated therein
by reference) for review and comment in a reasonable amount of time prior to any proposed filing and to file no such amendment or supplement
(other than any prospectus supplement relating to the offering of other securities (including, without limitation, Shares)) to which
the Manager shall have objected in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
To make available to the Manager, as soon as practicable after the date of this Agreement, and thereafter from time to time to furnish
to the Manager, as many copies of the Prospectus (or of the Prospectus as amended or supplemented at such time if the Company shall have
made any amendments or supplements thereto) as the Manager may reasonably request; in case the Manager are required to deliver (whether
physically, deemed to be delivered pursuant to Rule 153 or through compliance with Rule 172 under the Act or any similar rule), in connection
with the sale of the Shares, a prospectus after the nine-month period referred to in Section 10(a)(3) of the Act, or after the time a
post-effective amendment to the Registration Statement is required pursuant to Item 512(a) of Regulation S-K under the Act, the Company
will prepare, at its expense, such amendment or amendments to the Registration Statement and the Prospectus as may be necessary to ensure
compliance with the requirements of Section 10(a)(3) of the Act or Item 512(a) of Regulation S-K under the Act, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Subject to Section 4(b) hereof, to file promptly all reports and documents and any preliminary or definitive proxy or information statement
required to be filed by the Company with the Commission in order to comply with the Exchange Act for so long as a prospectus relating
to the Shares is required by the Act to be delivered (whether physically, deemed to be delivered pursuant to Rule 153 under the Act or
through compliance with Rule 172 under the Act or any similar rule) in connection with any sale of Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
To promptly notify the Manager of the happening of any event that could require the making of any change in the Prospectus as then amended
or supplemented so that the Prospectus would not include an untrue statement of material fact or omit to state a material fact necessary
in order to make the statements therein, in the light of the circumstances under which they are made, not misleading, and, during any
period during which a prospectus is required to be delivered (whether physically, deemed to be delivered pursuant to Rule 153 under the
Act or through compliance with Rule 172 under the Act or any similar rule) in connection with any sale of Shares, to prepare and furnish,
at the Company&rsquo;s expense, to the Manager promptly such amendments or supplements to such Prospectus as may be necessary to reflect
any such change in such quantities as the Manager may reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
To furnish such information as may be required and otherwise cooperate in qualifying the Shares for offer and sale under the securities
laws of such jurisdictions as the Manager may reasonably designate and to maintain such qualifications in effect so long as required
for the distribution of the Shares; <I>provided</I>, <I>however</I>, that the Company shall not be required to qualify as a foreign corporation
or to consent to the service of process under the laws of any such jurisdiction (except service of process with respect to the offering
and sale of the Shares); and to promptly advise the Manager of the receipt by the Company of any notification with respect to the suspension
of the qualification of the Shares for offer or sale in any jurisdiction or the initiation or threatening in writing of any proceeding
for such purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
To make generally available to the Company&rsquo;s security holders, and to deliver to the Manager, an earnings statement of the Company
covering a period of twelve months which will satisfy the provisions of Section 11(a) of the Act and Rule 158 thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
To apply the net proceeds from the sale of the Shares pursuant to this Agreement and any Terms Agreement in the manner set forth under
the caption &ldquo;<B>Use of Proceeds</B>&rdquo; in the Prospectus Supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
At any time that the Company has instructed the Manager to sell the Shares pursuant to Section 3(a)(i) hereof but such instructions have
not been fulfilled, settled or cancelled, not to sell, offer to sell, contract or agree to sell, hypothecate, pledge, grant any option
to sell or otherwise dispose of or agree to dispose of, directly or indirectly, any Common Shares or securities convertible into or exchangeable
or exercisable for Common Shares or warrants or other rights to purchase Common Shares or any other securities of the Company that are
substantially similar to the Common Shares or permit the registration under the Act of any Common Shares, in each case without giving
the Manager at least three business days&rsquo; prior written notice specifying the nature of the proposed sale and the date of such
proposed sale. Notwithstanding the foregoing, the Company may (i) register the offer and sale of the Shares through the Manager pursuant
to this Agreement or any Terms Agreement; (ii) issue Common Shares pursuant to employee benefit plans, qualified stock option plans or
other employee compensation plans existing on the date hereof; (iii) issue Common Shares in connection with the exercise of any warrants
outstanding prior to the Execution Date; or (iv) issue Common Shares in connection with any acquisition, <I>provided</I>, that in connection
with such issuance, the seller(s) agrees in writing to be bound by the provisions of this Section 4(i). In the event that notice of a
proposed sale is provided by the Company pursuant to this Section 4(i), the Manager may suspend activity under this program for such
period of time as may be requested by the Company or as may be deemed appropriate by the Manager.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
Not to take, and to cause each other Company Party not to take, directly or indirectly, any action designed to cause or result in, or
that has constituted or might reasonably be expected to constitute under the Exchange Act or otherwise, the stabilization or manipulation
of the price of Common Shares to facilitate the sale or resale of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
To use its commercially reasonable efforts to cause the Common Shares to maintain its listing on Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
To advise the Manager promptly after it receives notice or obtains knowledge of any information or fact that would materially alter or
affect any opinion, certificate, letter or other document provided to the Manager pursuant to Section 6 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
Upon commencement of the offering of the Shares under this Agreement (and upon recommencement of the offering of the Shares under this
Agreement following a Suspension Period) and promptly after each date that (i) the Registration Statement or the Prospectus is amended
or supplemented (other than pursuant to subclause (ii) below and other than by a prospectus supplement filed pursuant to Rule 424(b)
under the Act relating solely to the offering of securities other than the Shares), or (ii) there is filed with the Commission any document
incorporated by reference into the Prospectus (the date of commencement of the offering of the Shares under this Agreement and each date
referred to in subclauses (i) and (ii) above, are collectively referred to as a &ldquo;<B>Bring-Down Delivery Date</B>&rdquo;), to furnish
or cause to be furnished to the Manager forthwith a certificate dated and delivered on the Bring-Down Delivery Date, in form satisfactory
to the Manager, to the effect that the statements contained in the certificate referred to in Section 6(e) of this Agreement that was
last furnished to the Manager are true and correct as of such Bring-Down Delivery Date, as though made at and as of such date (except
that such statements shall be deemed to relate to the Registration Statement and the Prospectus as amended and supplemented to such date)
or, in lieu of such certificate, a certificate of the same tenor as the certificate referred to in said Section 6(e), modified as necessary
to relate to the Registration Statement and the Prospectus as amended and supplemented to the time of delivery of such certificate; <I>provided
</I>that the filing of a Current Report on Form 8-K will not constitute a Bring-Down Delivery Date under clause (ii) above unless either
(A)(x) such Current Report on Form 8-K is filed at any time during which either a prospectus relating to the Shares is required to be
delivered under the Act (whether physically, deemed to be delivered pursuant to Rule 153 under the Act or through compliance with Rule
172 under the Act or any similar rule) or such Current Report on Form 8-K is filed at any time from and including the date of a Terms
Agreement through and including the relevant Settlement Date and (y) the Manager has reasonably requested that such date be deemed to
be a Bring-Down Delivery Date based upon the event or events reported in such Current Report on Form 8-K or (B) such Current Report on
Form 8-K contains capsule financial information, historical or pro forma financial statements, supporting schedules or other financial
data, including any Current Report on Form 8-K or part thereof under Item 2.02 of Regulation S-K of the Commission that is considered
&ldquo;filed&rdquo; under the Exchange Act; and <I>provided</I>, <I>further</I>, that the obligation of the Company under this subsection
(m) shall be deferred during any Suspension Period and shall recommence upon the termination of such Suspension Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
To furnish or cause to be furnished forthwith to the Manager (i) at or promptly after each Bring-Down Delivery Date (and upon recommencement
of the offering of the Shares under this Agreement following a Suspension Period), a written opinion letter (including negative assurance)
of Dickinson Wright LLP, counsel for the Company, or other counsel satisfactory to the Manager (the &ldquo;<B>Company Counsel</B>&rdquo;),
dated and delivered as of such Bring-Down Delivery Date, in form and substance satisfactory to the Manager, of the same tenor as the
opinions referred to in Section 6(c) of this Agreement, but modified as necessary to relate to the Registration Statement and the Prospectus
as amended and supplemented to the time of delivery of such opinions; <I>provided</I>, <I>however</I>, that in lieu of such opinions
for subsequent Bring-Down Delivery Date that a Company Counsel is required to deliver, such Company Counsel may furnish the Manager with
a letter to the effect that the Manager may rely on a prior opinion delivered under this Section 4(n) to the same extent as if it were
dated the date of such letter (except that statements in such prior opinion shall be deemed to relate to the Registration Statement and
the Prospectus as amended or supplemented at such Bring-Down Delivery Date); <I>provided further</I> that the obligation of the Company
under this subsection (n) shall be deferred during any Suspension Period and shall recommence upon the termination of such Suspension
Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
Upon commencement of the offering of the Shares under this Agreement, to furnish or cause to be furnished forthwith to the Manager a
written opinion letter of the Company&rsquo;s in-housel legal counsel with respect to intellectual property matters, in form and substance
satisfactory to the Manager.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
At or promptly after each Bring-Down Delivery Date (and upon recommencement of the offering of the Shares under this Agreement following
a Suspension Period), Goodwin Procter LLP, counsel to the Manager, shall deliver a negative assurance letter, dated and delivered as
of such Bring-Down Delivery Date, in form and substance satisfactory to the Manager; <I>provided</I> that the obligation under this subsection
(p) shall be deferred during any Suspension Period and shall recommence upon the termination of such Suspension Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
Upon commencement of the offering of the Shares under this Agreement (and upon recommencement of the offering of the Shares under this
Agreement following a Suspension Period), and or promptly after each date that (i) the Registration Statement or the Prospectus shall
be amended or supplemented to include additional or amended financial information and (ii) the Company shall file an annual report on
Form 10-K (including any Form 10-K/A containing amended financial information or a material amendment to the previously filed Form 10-K)
or a quarterly report on Form 10-Q, (iii) there is filed with the Commission any document (other than an annual report on Form 10-K or
a quarterly report on Form 10-Q) incorporated by reference into the Prospectus which contains financial information, the Manager shall
make a reasonable request therefor, to cause the Accountant, or other independent accountants satisfactory to the Manager, forthwith
to furnish to the Manager a letter (&ldquo;<B>Comfort Letter</B>&rdquo;), dated the date of the commencement of the offering, the date
of effectiveness of such amendment, the date of filing of such supplement or other document with the Commission, as the case may be,
in form and substance satisfactory to the Manager, of the same tenor as the letter referred to in Section 6(d) of this Agreement but
modified to relate to the Registration Statement and the Prospectus, as amended and supplemented to the date of such letter; <I>provided
</I>that the obligation of the Company under this subsection (q) shall be deferred during any Suspension Period and shall recommence
upon the termination of such Suspension Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
That the Company acknowledges that the Manager may trade in Common Shares for the Manager&rsquo;s own account and for the account of
its clients at the same time as sales of the Shares occur pursuant to this Agreement; <I>provided, </I>that such activity of the Manager
is conducted in compliance with Regulation M under the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
If, to the knowledge of the Company, any condition set forth in Section 6(a) or 6(h) hereof shall not have been satisfied on the applicable
Settlement Date, to offer to any person who has agreed to purchase the Shares from the Company as the result of an offer to purchase
solicited by the Manager the right to refuse to purchase and pay for such Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
To disclose in its quarterly reports on Form 10-Q and in its annual report on Form 10-K the number of the Shares sold through or to the
Manager under this Agreement, the Net Proceeds to the Company and the compensation paid to the Manager by the Company with respect to
sales of the Shares pursuant to this Agreement during the period covered by the report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)
At each Bring-Down Delivery Date, to conduct a due diligence session, in form and substance, satisfactory to the Manager, which shall
include representatives of the management and the accountants of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
To ensure that, prior to instructing the Manager to sell Shares, the Company shall have obtained all necessary corporate authority for
the offer and sale of such Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)
If, immediately prior to the third anniversary of the effectiveness of the Registration Statement, any of the Shares remain unsold hereunder,
the Company will, prior to such third anniversary, file a new prospectus supplement (the &ldquo;<B>New Prospectus Supplement</B>&rdquo;)
relating to the Shares to its subsequent registration statement on Form S-3 (the &ldquo;<B>Subsequent Registration Statement</B>&rdquo;),
and will take all other reasonable actions necessary or appropriate to permit the offering and sale of the Shares to continue as contemplated
in the expired registration statement relating to such Shares and this Agreement. Upon filing of the New Prospectus Supplement, except
where the context otherwise requires, references herein to the &ldquo;Registration Statement&rdquo; shall be deemed to refer to the Subsequent
Registration Statement, and references herein to the &ldquo;Prospectus Supplement&rdquo; shall be deemed to refer to the New Prospectus
Supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
5: <U>Payment of Expenses</U>. Except as otherwise agreed in writing among the Company and the Manager, the Company agrees, whether or
not the transactions contemplated hereunder are consummated or this Agreement is terminated, to pay all of the Company&rsquo;s expenses
incident to the performance of its obligations hereunder, including, but not limited to, such costs, expenses, fees and taxes in connection
with (i) the preparation and filing of the Registration Statement, the Base Prospectus, the Prospectus Supplement, the Prospectus and
any amendments or supplements thereto, and the printing and furnishing of copies of each such document to the Manager (including costs
of mailing and shipment), (ii) the registration, issue, sale and delivery of the Shares including any stock or transfer taxes and stamp
or similar duties payable upon the sale, issuance or delivery of the Shares, (iii) the producing, word processing and/or printing of
this Agreement, any Powers of Attorney and any closing documents (including compilations thereof) and the reproduction and/or printing
and furnishing of copies of each such document to the Manager (including costs of mailing and shipment), (iv) the qualification of the
Shares for offering and sale under state laws and the determination of their eligibility for investment under state or foreign law as
aforesaid and the printing and furnishing of copies of any blue sky surveys to the Manager, (v) the listing of the Shares on Nasdaq,
(vi) any filing for review of the public offering of the Shares by FINRA, including the reasonable legal fees and disbursements of counsel
for the Manager relating to FINRA matters and (vii) the reasonable fees and disbursements of the Company&rsquo;s counsel and of the Company&rsquo;s
accountants. The Manager will pay all of its out-of-pocket costs and expenses incurred in connection with entering into this Agreement
and the transactions contemplated by this Agreement, including, without limitation, travel, reproduction, printing and similar expenses;
provided, however, that the Company will reimburse (x) all fees, costs and expenses of external counsel to the Manager, in an amount
of up to $75,000 in the aggregate, payable upon execution of this Agreement, plus an additional $5,000 per calendar quarter, and (y)
the filing fees and expenses in connection with filings with the FINRA Corporate Financing Department, upon request from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
6: <U>Conditions of the Manager&rsquo;s Obligations</U>. The obligations of the Manager are subject to (i) the accuracy of the representations
and warranties of the Company as of each Representation Date, (ii) the performance by the Company of its obligations hereunder and (iii)
to the following additional conditions precedent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
(i) No stop order with respect to the effectiveness of the Registration Statement shall have been issued under the Act or proceedings
initiated under Section 8(d) or 8(e) of the Act, and no order directed at or in relation to any document incorporated by reference therein
and no order preventing or suspending the use of the Prospectus has been issued by the Commission, and no suspension of the qualification
of the Shares for offer or sale in any jurisdiction, or, to the knowledge of the Company or the Manager, of the initiation or threatening
in writing of any proceedings for any of such purposes, has occurred; (ii) the Registration Statement and all amendments thereto shall
not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make
the statements therein not misleading; (iii) neither the Base Prospectus nor the Prospectus, and no amendment or supplement thereto,
shall include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they are made, not misleading; and (iv) no Permitted Free Writing Prospectus and no amendment
or supplement thereto, shall include an untrue statement of a material fact or omit to state a material fact necessary in order to make
the statements therein, in the light of the circumstances under which they are made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Subsequent to the respective dates as of which information is given in the Registration Statement, the Base Prospectus and the Prospectus,
there shall not have been any Material Adverse Effect, in the judgment of the Manager.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
On every date specified in Section 4(n) hereof, the Manager shall have received an opinion and, as applicable, the negative assurance
letter of each Company Counsel, in form and substance satisfactory to the Manager, dated as of such date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
On every date specified in Section 4(q) hereof, the Manager shall have received from the Accountant, in form and substance satisfactory
to the Manager, a Comfort Letter, dated as of such date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
On every date specified in Section 4(m) hereof, the Manager shall have received a certificate to the effect that (i) the representations
and warranties of the Company as set forth in this Agreement are true and correct as of the Bring-Down Delivery Date, (ii) the Company
has performed its obligations under this Agreement that it is required to perform on or prior to such Bring-Down Delivery Date, and (iii)
the conditions set forth in paragraphs (a) and (b) of Section 6 hereof have been met. The certificate shall also state that the Shares
have been duly and validly authorized by the Company, that all company action required to be taken for the issuance and sale of the Shares
has been validly and sufficiently taken, and that the Company&rsquo;s board of directors, or a duly authorized committee thereof, has
not revoked, rescinded or otherwise modified or withdrawn such authorization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
On every date specified in Section 4(p) hereof, the Manager shall have received a negative assurance letter of Goodwin Procter LLP, counsel
to the Manager, in form and substance satisfactory to the Manager, dated as of such date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
All filings with the Commission required by Rule 424 under the Act to have been filed by any Settlement Date shall have been made within
the applicable time period prescribed for such filing by Rule 424.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
The Company shall have filed an application for listing of the Shares on Nasdaq prior to the sale of any Shares hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
7: <U>Indemnification and Contribution</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company agrees to indemnify, defend and hold harmless the Manager, its partners, employees, agents, members, directors and officers,
any person who controls the Manager within the meaning of Section 15 of the Act or Section 20 of the Exchange Act, and any &ldquo;affiliate&rdquo;
(within the meaning of Rule 405 under the Act) of the Manager that has, or is alleged to have, participated in the distribution of Shares,
and the successors and assigns of all the foregoing persons, from and against any loss, damage, expense, liability or claim (including,
without limitation, the reasonable cost of investigation and any legal fees and other expenses reasonably incurred in connection with
any suit, action, investigation or proceeding or any claim asserted), joint or several, which the Manager or any such person may incur
under the Act, the Exchange Act, the common law or otherwise, insofar as such loss, damage, expense, liability or claim arises out of
or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement (or
in the Registration Statement as amended by any post-effective amendment thereof by the Company) or arises out of or is based upon any
omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading,
except insofar as any such loss, damage, expense, liability or claim arises out of or is based upon any untrue statement or alleged untrue
statement of a material fact contained in, and in conformity with information furnished in writing by or on behalf of the Manager to
the Company expressly for use in, the Registration Statement or arises out of or is based upon any omission or alleged omission to state
a material fact in the Registration Statement in connection with such information, which material fact was not contained in such information
and which material fact was required to be stated in such Registration Statement or was necessary to make such information not misleading
or (ii) any untrue statement or alleged untrue statement of a material fact included in any Prospectus (the term Prospectus for the purpose
of this Section 7 being deemed to include the Base Prospectus, the Prospectus Supplement, the Prospectus and any amendments or supplements
to the foregoing), in any &ldquo;issuer information&rdquo; (as defined in Rule 433 under the Act) of the Company, in any road show as
defined under Rule 433(h) under the Act (a &ldquo;<B>road show</B>&rdquo;) or in any Permitted Free Writing Prospectus, or that arises
out of or is based upon any omission or alleged omission to state a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading, except, with respect to such Prospectus, insofar as any
such loss, damage, expense, liability or claim arises out of or is based upon any untrue statement or alleged untrue statement of a material
fact contained in, and in conformity with information furnished in writing by or on behalf of the Manager to the Company expressly for
use in, such Prospectus or arises out of or is based upon any omission or alleged omission to state a material fact in such Prospectus
in connection with such information, which material fact was not contained in such information and which material fact was necessary
in order to make the statements in such information, in the light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any action, suit, inquiry or proceeding (together, a &ldquo;<B>Proceeding</B>&rdquo;) is brought against the Manager or any such person
in respect of which indemnity may be sought against the Company pursuant to the foregoing paragraph, the Manager or such person shall
promptly notify the Company in writing of the institution of such Proceeding and the Company shall assume the defense of such Proceeding,
including the employment of counsel reasonably satisfactory to such indemnified party and payment of all fees and expenses; provided,
however, that the omission to so notify the Company shall not relieve the Company from any liability which the Company may have to the
Manager or any such person or otherwise except to the extent the Company was materially prejudiced by such omission. The Manager or such
person shall have the right to employ its or their own counsel in any such case, but the fees and expenses of such counsel shall be at
the expense of the Manager or of such person unless the employment of such counsel shall have been authorized in writing by the Company
in connection with the defense of such Proceeding or the Company shall not have, within a reasonable period of time in light of the circumstances,
employed counsel to have charge of the defense of such Proceeding or such indemnified party or parties shall have reasonably concluded
that there may be defenses available to it or them which are different from, additional to or in conflict with those available to the
Company (in which case the Company shall not have the right to direct the defense of such Proceeding on behalf of the indemnified party
or parties), in any of which events such fees and expenses shall be borne by the Company, and paid as incurred (it being understood,
however, that the Company shall not be liable for the expenses of more than one separate counsel (in addition to any local counsel) in
any one Proceeding or series of related Proceedings in the same jurisdiction representing the indemnified parties who are parties to
such Proceeding). The Company shall not be liable for any settlement of any Proceeding effected without its written consent but, if settled
with the written consent of the Company, the Company agrees to indemnify and hold harmless the Manager and any such person from and against
any loss or liability by reason of such settlement. Notwithstanding the foregoing sentence, if at any time an indemnified party shall
have requested the Company to reimburse the indemnified party for fees and expenses of counsel as contemplated by the second sentence
of this paragraph, then the Company agrees that it shall be liable for any settlement of any Proceeding effected without its written
consent if (i) such settlement is entered into more than 60 business days after receipt by the Company of the aforesaid request, (ii)
the Company shall not have reimbursed the indemnified party in accordance with such request prior to the date of such settlement and
(iii) such indemnified party shall have given the indemnifying party at least 30 days&rsquo; prior notice of its intention to settle.
The Company shall not, without the prior written consent of the indemnified party, effect any settlement of any pending or threatened
Proceeding in respect of which any indemnified party is or may be a party and indemnity could have been sought hereunder by such indemnified
party, unless such settlement includes an unconditional release of such indemnified party from all liability on claims that are the subject
matter of such Proceeding and does not include any statement as to or an admission of fault, culpability or a failure to act, by or on
behalf of such indemnified party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Manager agrees to indemnify and hold harmless the Company and its respective partners, employees, agents, members, directors and
each officer that signed the Registration Statement, each person, if any, who controls the Company within the meaning of Section 15 of
the Act or Section 20 of the Exchange Act, and the successors and assigns of all of the foregoing persons from and against any loss,
damage, expense, liability or claim (including, without limitation, the reasonable cost of investigation and any legal fees and other
expenses reasonably incurred in connection with any suit, action, investigation or proceeding or any claim asserted), joint or several,
which the Company or any such person may incur under the Act, the Exchange Act, the common law or otherwise, insofar as such loss, damage,
expense, liability or claim arises out of or is based upon any untrue statement or alleged untrue statement of a material fact made in
reliance upon and in conformity with any information relating to the Manager furnished in writing by or on behalf of the Manager to the
Company expressly for use with reference to the Manager in the Prospectus or arising out of or is based upon any omission or alleged
omission to state a material fact therein in connection with such information, which material fact was not contained in such information
and which material fact was necessary in order to make the statements in such information, in the light of the circumstances under which
they were made, not misleading, it being understood and agreed that the only such information furnished by the Manager consists of the
following information in the Prospectus furnished on behalf of the Manager: the second sentence of the eighth paragraph under the caption
&ldquo;Plan of Distribution.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any Proceeding is brought against the Company or any such person in respect of which indemnity may be sought against the Manager pursuant
to the foregoing paragraph, such Company or such person shall promptly notify the Manager in writing of the institution of such Proceeding
and the Manager shall assume the defense of such Proceeding, including the employment of counsel reasonably satisfactory to such indemnified
party and payment of all fees and expenses; provided, however, that the omission to so notify the Manager shall not relieve the Manager
from any liability which the Manager may have to the Company or any such person or otherwise. The Company or such person shall have the
right to employ its own counsel in any such case, but the fees and expenses of such counsel shall be at the expense of the Company or
such person unless the employment of such counsel shall have been authorized in writing by the Manager in connection with the defense
of such Proceeding or the Manager shall not have, within a reasonable period of time in light of the circumstances, employed counsel
to have charge of the defense of such Proceeding or such indemnified party or parties shall have reasonably concluded that there may
be defenses available to it or them which are different from or additional to or in conflict with those available to the Manager (in
which case the Manager shall not have the right to direct the defense of such Proceeding on behalf of the indemnified party or parties,
but the Manager may employ counsel and participate in the defense thereof but the fees and expenses of such counsel shall be at the expense
of the Manager), in any of which events such fees and expenses shall be borne by the Manager and paid as incurred (it being understood,
however, that the Manager shall not be liable for the expenses of more than one separate counsel (in addition to any local counsel) in
any one Proceeding or series of related Proceedings in the same jurisdiction representing the indemnified parties who are parties to
such Proceeding). The Manager shall not be liable for any settlement of any such Proceeding effected without the written consent of the
Manager but, if settled with the written consent of the Manager or if there be a final judgment for the plaintiff, the Manager agrees
to indemnify and hold harmless the Company and any such person from and against any loss or liability by reason of such settlement or
judgment. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested the Manager to reimburse the
indemnified party for fees and expenses of counsel as contemplated by the second sentence of this paragraph, then the Manager agrees
that it shall be liable for any settlement of any Proceeding effected without its written consent if (i) such settlement is entered into
more than 60 business days after receipt by the Manager of the aforesaid request, (ii) the Manager shall not have reimbursed the indemnified
party in accordance with such request prior to the date of such settlement and (iii) such indemnified party shall have given the Manager
at least 30 days&rsquo; prior notice of its intention to settle. The Manager shall not, without the prior written consent of the indemnified
party, effect any settlement of any pending or threatened Proceeding in respect of which any indemnified party is a party and indemnity
could have been sought hereunder by such indemnified party, unless such settlement includes an unconditional release of such indemnified
party from all liability on claims that are the subject matter of such Proceeding and does not include any statement as to or an admission
of fault, culpability or a failure to act, by or on behalf of such indemnified party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
If the indemnification provided for in this Section 7 is unavailable to an indemnified party under subsections (a) and (b) of this Section
7 or insufficient to hold an indemnified party harmless in respect of any losses, damages, expenses, liabilities or claims referred to
therein, then the indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of such losses,
damages, expenses, liabilities or claims (i) in such proportion as is appropriate to reflect the relative benefits received by the Company,
on the one hand, and the Manager, on the other hand, from the offering of the Shares or (ii) if the allocation provided by clause (i)
above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to
in clause (i) above but also the relative fault of the Company, on the one hand, and of the Manager, on the other, in connection with
the statements or omissions which resulted in such losses, damages, expenses, liabilities or claims, as well as any other relevant equitable
considerations. The relative benefits received by the Company, on the one hand, and the Manager, on the other, shall be deemed to be
in the same respective proportions as the total proceeds from the offering (net of commissions paid hereunder but before deducting expenses)
received by the Company, and the total commissions received by the Manager hereunder, bear to the aggregate public offering price of
the Shares. The relative fault of the Company, on the one hand, and of the Manager, on the other, shall be determined by reference to,
among other things, whether the untrue statement or alleged untrue statement of a material fact or omission or alleged omission relates
to information supplied by the Company or by the Manager and the party&rsquo;s relative intent, knowledge, access to information and
opportunity to correct or prevent such statement or omission. The amount paid or payable by a party as a result of the losses, damages,
expenses, liabilities and claims referred to in this subsection (c) shall be deemed to include any legal or other fees or expenses reasonably
incurred by such party in connection with investigating, preparing to defend or defending any Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
The Company and the Manager agree that it would not be just and equitable if contributions pursuant to this Section 7 were determined
by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in
subsection (c) above. Notwithstanding the provisions of this Section 7, no Manager shall be required to contribute any amount in excess
of commissions received by it under this Agreement. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f)
of the Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
The Company and the Manager agree promptly to notify each other of the commencement of any Proceeding against it and, in the case of
the Company, against any of the Company&rsquo;s officers or directors in connection with the issuance and sale of the Shares, or in connection
with the Registration Statement, the Base Prospectus or the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
8: <U>Representations and Agreements to Survive Delivery</U>. The indemnity and contribution agreements contained in Section 7 hereof
and the covenants, warranties and representations of the Company contained in this Agreement or in certificates delivered pursuant hereto
shall remain in full force and effect regardless of any investigation made by or on behalf of the Manager, its partners, directors or
officers or any person (including each partner, officer or director of such person) who controls the Manager within the meaning of Section
15 of the Act or Section 20 of the Exchange Act, or by or on behalf of the Company, its directors or officers or any person who controls
the Company within the meaning of Section 15 of the Act or Section 20 of the Exchange Act, and shall survive any termination of this
Agreement or the issuance and delivery of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
9: <U>Termination</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company shall have the right, by giving written notice as hereinafter specified, to terminate this Agreement in its sole discretion
at any time. Any such termination shall be without liability of any party to any other party, except that (i) with respect to any pending
sale, through the Manager for the Company, the obligations of the Company, including in respect of compensation of the Manager, shall
remain in full force and effect notwithstanding the termination and (ii) the provisions of Sections 5, 7, 8, 10, 11, 12, 18 and 20 hereof
shall remain in full force and effect notwithstanding such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Manager shall have the right, by giving written notice as hereinafter specified, to terminate the provisions of this Agreement relating
to the solicitation of offers to purchase the Shares in its sole discretion at any time. Any such termination shall be without liability
of any party to any other party, except that the provisions of Sections 5, 7, 8, 10, 11, 12, 18 and 20 hereof shall remain in full force
and effect notwithstanding such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
This Agreement shall remain in full force and effect unless terminated pursuant to Sections 9(a) or (b) above or otherwise by mutual
agreement of the parties; <I>provided</I> that any such termination by mutual agreement shall in all cases be deemed to provide that
Sections 5, 7 and 8 hereof shall remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Any termination of this Agreement shall be effective on the date specified in such notice of termination; <I>provided</I> that such termination
shall not be effective until the close of business on the date of receipt of such notice by the Manager or the Company, as the case may
be. If such termination shall occur prior to the Settlement Date for any sale of the Shares, such sale shall settle in accordance with
the provisions of Section 3(a)(vi) hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Unless earlier terminated pursuant to this Section 9, this Agreement shall automatically terminate upon the issuance and sale of all
of the Shares through the Manager on the terms and subject to the conditions set forth herein, except that Sections 5, 7, 8, 10, 11,
12, 18 and 20 and shall remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
10: <U>Notices</U>. Except as otherwise herein provided, all statements, requests, notices and agreements under this Agreement shall
be in writing and delivered by hand, overnight courier, mail or transmitted by any standard form of telecommunication and, if to the
Manager, shall be sufficient in all respects if delivered or sent to Canaccord Genuity LLC, 99 High Street, 12<SUP>th</SUP> Floor, Boston,
Massachusetts 02110, Attention: ECM, General Counsel (email: aviles@cgf.com); and, if sent to the Company, shall be delivered or sent
to Enveric Biosciences, Inc., 4851 Tamiami Train N, Suite 200, Naples, Florida 34103 (email: kcoveney@enveric.com). Each party to this
Agreement may change such address for notices by sending to the parties to this Agreement written notice of a new address for such purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
11: <U>Parties at Interest</U>. The Agreement herein set forth has been and is made solely for the benefit of the Company and the Manager
and, to the extent provided in Section 7 hereof, the controlling persons, directors and officers referred to in such section, and their
respective successors, assigns, heirs, personal representatives and executors and administrators. No other person, partnership, association
or corporation (including a purchaser, as such purchaser, through or from the Manager) shall acquire or have any right under or by virtue
of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
12: <U>No Fiduciary Relationship</U>. The Company hereby acknowledges that the Manager is acting solely as sales agent and/or principal
in connection with the purchase and sale of the Shares. The Company further acknowledges that the Manager is acting pursuant to a contractual
relationship created solely by this Agreement entered into on an arm&rsquo;s length basis, and in no event do the parties intend that
the Manager act or be responsible as a fiduciary to the Company, the management, stockholders or creditors or any other person in connection
with any activity that the Manager may undertake or have undertaken in furtherance of the purchase and sale of the Company&rsquo;s securities,
either before or after the date hereof. The Manager hereby expressly disclaims any fiduciary or similar obligations to the Company, either
in connection with the transactions contemplated by this Agreement or any matters leading up to such transactions, and the Company hereby
confirms its understanding and agreement to that effect. The Company and the Manager agree that each is responsible for making its own
independent judgments with respect to any such transactions and that any opinions or views expressed by the Manager to the Company regarding
such transactions, including, but not limited to, any opinions or views with respect to the price or market for the Company&rsquo;s securities,
do not constitute advice or recommendations to the Company. The Company hereby waives and releases, to the fullest extent permitted by
law, any claims that the Company may have against the Manager with respect to any breach or alleged breach of any fiduciary or similar
duty to the Company in connection with the transactions contemplated by this Agreement or any matters leading up to such transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
13: <U>Press Releases and Disclosure</U>. The Company may issue a press release in compliance with Rule 134 under the Act describing
the material terms of the transactions contemplated hereby as soon as practicable following the date hereof and may file with the Commission
a Current Report on Form 8-K describing the material terms of the transaction contemplated hereby, and the Company shall consult with
the Manager prior to making such disclosures, and the parties shall use commercially reasonable efforts, acting in good faith, to agree
upon the text of such disclosure that is reasonably satisfactory to all parties. No party hereto shall issue thereafter any press release
or like public statement (including, without limitation, any disclosure required in reports filed with the Commission pursuant to the
Exchange Act) related to this Agreement or any of the transactions contemplated hereby without the prior written approval of the other
party, except as may be necessary or appropriate in the opinion of the party seeking to make disclosure to comply with the requirements
of applicable law or Commission or Nasdaq rules. If any such press release or like public statement is so required, the party making
such disclosure shall consult with the other party prior to making such disclosure, and the parties shall use commercially reasonable
efforts, acting in good faith, to agree upon the text of such disclosure that is reasonably satisfactory to all parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
14: <U>Adjustments for Share Splits</U>. The parties acknowledge and agree that all share-related numbers contained in this Agreement
shall be adjusted to take into account any share split, share dividend or similar event effected with respect to the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
15: <U>Entire Agreement</U>. This Agreement constitutes the entire agreement and supersedes all other prior and contemporaneous agreements
and undertakings, both written and oral, among the parties hereto with regard to the subject matter hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
16: <U>Counterparts</U>. This Agreement may be signed by the parties in one or more counterparts which together shall constitute one
and the same agreement among the parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
17: <U>Electronic Signature</U>. The words &ldquo;execution,&rdquo; &ldquo;signed,&rdquo; &ldquo;signature,&rdquo; and words of like
import in this Agreement or in any amendment or other modification hereof (including waivers and consents) shall be deemed to include
electronic signatures or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability
as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided
for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic
Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
18: <U>Law; Construction</U>. This Agreement and any claim, counterclaim or dispute of any kind or nature whatsoever arising out of or
in any way relating to this Agreement, directly or indirectly, shall be governed by, and construed in accordance with, the internal laws
of the State of New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
19: <U>Headings</U>. The Section headings in this Agreement have been inserted as a matter of convenience of reference and are not a
part of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
20: <U>Applicable Law and Submission to Jurisdiction</U>. This Agreement and any claim, controversy or dispute arising under or related
to this Agreement or the transactions contemplated hereby (including without limitation, any claims sounding in equity, statutory law,
contract law or tort law arising out of the subject matter hereof) shall be governed by and construed in accordance with the laws of
the State of New York, without giving effect to its conflicts of laws doctrine. Any legal suit, action or proceeding arising out of or
based upon this Agreement or the transactions contemplated hereby may be instituted in the federal courts of the United States of America
located in the Borough of Manhattan in the City of New York or the courts of the State of New York in each case located in the Borough
of Manhattan in the City of New York (collectively, the &ldquo;<B>Designated Courts</B>&rdquo;), and each party irrevocably submits to
the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such court, as to which
such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding. Service of any process, summons, notice or
document by mail to such party&rsquo;s address set forth above shall be effective service of process for any suit, action or other proceeding
brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action
or other proceeding in the Designated Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court
that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
21: <U>Successors and Assigns</U>. This Agreement shall be binding upon the Company and the Manager and their respective successors and
assigns and any successor or assign of any substantial portion of the Company&rsquo;s and the Manager&rsquo;s respective businesses and/or
assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
22: <U>Recognition of the U.S. Special Resolution Regimes</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
In the event that the Manager qualifies as a Covered Entity and becomes subject to a proceeding under a U.S. Special Resolution Regime,
the transfer from the Manager of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the
same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and
obligation, were governed by the laws of the United States or a state of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
In the event that the Manager qualifies as a Covered Entity and becomes subject, or a BHC Act Affiliate of the Manager becomes subject,
to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against the Manager
are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime
if this Agreement were governed by the laws of the United States or a state of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this Section 22: (A) a &ldquo;BHC Act Affiliate&rdquo; has the meaning assigned to the term &ldquo;affiliate&rdquo; in, and
shall be interpreted in accordance with, 12 U.S.C. &sect; 1841(k); (B) &ldquo;Covered Entity&rdquo; means any of the following: (i) a
&ldquo;covered entity&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 252.82(b); (ii) a &ldquo;covered
bank&rdquo; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 47.3(b); or (iii) a &ldquo;covered FSI&rdquo;
as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect; 382.2(b); (C) &ldquo;Default Right&rdquo; has the meaning
assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect; 252.81, 47.2 or 382.1, as applicable; and
(D) &ldquo;U.S. Special Resolution Regime&rdquo; means each of (i) the Federal Deposit Insurance Act and the regulations promulgated
thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECTION
23: <U>Miscellaneous</U>. Securities sold, offered or recommended by the Manager are not deposits, are not insured by the Federal Deposit
Insurance Corporation, are not guaranteed by a branch or agency, and are not otherwise an obligation or responsibility of a branch or
agency. Lending affiliates of the Manager have or may in the future have lending relationships with issuers of securities underwritten
or privately placed by the Manager. Prospectuses and other disclosure documents for securities underwritten or privately placed by the
Manager may disclose the existence of any such lending relationships and whether the proceeds of the issue may be used to repay debts
owed to affiliates of the Manager.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Signature
Pages Follow</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the foregoing correctly sets forth the understanding between the Company and the Manager, please so indicate in the space provided below
for that purpose, whereupon this Agreement and your acceptance shall constitute a binding agreement between the Company and the Manager.
Alternatively, the execution of this Agreement by the Company and its acceptance by or on behalf of the Manager may be evidenced by an
exchange of telegraphic or other written communications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ENVERIC
    BIOSCIENCES, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT><P STYLE="margin-top: 0; margin-bottom: 0"></P>
                                                         <P STYLE="margin-top: 0; margin-bottom: 0"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
    Tucker, PhD</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">ACCEPTED as of the date</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">first above written</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold">CANACCORD GENUITY LLC</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 45%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Name:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Title:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Schedule
A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Permitted
Free Writing Prospectuses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Schedule
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Authorized
Company Representatives</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
    Tucker, PhD</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kevin
    Coveney</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Schedule
C</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jurisdiction
    of Organization</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
    Biosciences, Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware,
    USA</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jay
    Pharma Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ontario,
    Canada </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1306432
    B.C. Unlimited Liability Company</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">British
    Columbia, Canada</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
    Biosciences Canada, Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">British
    Columbia, Canada</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed
    USA, Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Massachusetts,
    USA</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Akos
    Biosciences, Inc.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware,
    USA</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
    Therapeutics Pty. Ltd.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adelaide,
    Australia</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
3(a)(i)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
    Biosciences, Inc.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canaccord
    Genuity LLC</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At-the-Market
    Offering</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms and subject to the conditions contained in the Equity Distribution Agreement among Enveric Biosciences, Inc., a Delaware
corporation (the &ldquo;<B>Company</B>&rdquo;) and Canaccord Genuity LLC (the &ldquo;<B>Manager</B>&rdquo;) dated September 1, 2023 (the
&ldquo;<B>Agreement</B>&rdquo;), I hereby request on behalf of the Company that the Manager sell up to [&#9679;] shares of common stock
of the Company, par value $0.01 per share (the &ldquo;<B>Shares</B>&rdquo;) at a minimum market price of $[&#9679;] per Share between
[&nbsp;&nbsp;], 20[&nbsp;&nbsp;] and [&nbsp;&nbsp;], 20[&nbsp;&nbsp;]. [There shall be no limitation on the number of Shares that may be sold on any one (1) day.][No more than [&#9679;]
Shares may be sold on any one (1) day.] [Other sales parameters]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Very truly yours,</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 45%">&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp;</TD>
    <TD>[________________]</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD> [________________]</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 33; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ex5-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 5.1</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD ROWSPAN="5" STYLE="font: small-caps 10pt Times New Roman, Times, Serif; letter-spacing: 1pt; width: 50%"><IMG SRC="ex5-1_001.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></TD>
    <TD STYLE="font: small-caps 10pt Times New Roman, Times, Serif; letter-spacing: 1pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">1850
    North Central Ave., Suite 1400</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: small-caps 10pt Times New Roman, Times, Serif; letter-spacing: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Phoenix,
    AZ 85004</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: small-caps 10pt Times New Roman, Times, Serif; letter-spacing: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Telephone:
    (602) 285-5000</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: small-caps 10pt Times New Roman, Times, Serif; letter-spacing: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Facsimile:
    (844) 670-6009</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; letter-spacing: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">http://www.dickinsonwright.com</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><BR STYLE="clear: both"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">September
1, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Enveric
Biosciences, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">4851
Tamiami Trail N, Suite 200</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Naples,
FL 34103</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B><I>Re:
Securities Registered under Registration Statement on Form S-3 (File No. 333-257690)</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">You
have requested our opinion with respect to certain matters in connection with the proposed offer and sale by Enveric Biosciences, Inc.,
a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), of up to an aggregate of $2,392,514 of shares of the Company&rsquo;s common
stock, par value $0.01 per share (the &ldquo;<B>Placement Shares</B>&rdquo;), pursuant to a Registration Statement on Form S-3 (File
No. 333-257690) (the &ldquo;<B>Registration Statement</B>&rdquo;), which was originally filed under the Securities Act of 1933, as amended
(the &ldquo;<B>Securities Act</B>&rdquo;), with the Securities and Exchange Commission (&ldquo;<B>SEC</B>&rdquo;) on July 2, 2021 and
declared effective by the SEC on July 9, 2021, the base prospectus contained in the Registration Statement (the &ldquo;<B>Base Prospectus</B>&rdquo;),
and the prospectus supplement relating to the proposed offer and sale of the Placement Shares filed with the SEC September 1, 2023 pursuant
to Rule 424(b) of the rules and regulations under the Securities Act (the &ldquo;<B>Prospectus Supplement</B>,&rdquo; and together with
the Base Prospectus, the &ldquo;<B>Prospectus</B>&rdquo;). We understand that the Placement Shares are proposed to be offered and sold
by the Company through Canaccord Genuity LLC (&ldquo;<B>Agent</B>&rdquo;) pursuant to the Equity Distribution Agreement dated September
1, 2023, by and between the Company and Agent (the &ldquo;<B>Distribution Agreement</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In
connection with the preparation of this opinion, we have examined such documents and considered such questions of law as we have deemed
necessary or appropriate. We have assumed the authenticity of all documents submitted to us as originals, the conformity to originals
of all documents submitted to us as copies thereof and the genuineness of all signatures. As to questions of fact material to our opinions,
we have relied upon the certificates of certain officers of the Company without independent investigation or verification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Based
on the foregoing, we are of the opinion that the Placement Shares have been duly authorized and, when issued and sold in the manner described
in the Registration Statement, the Prospectus and the Distribution Agreement, will be validly issued, fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><IMG SRC="ex5-1_002.jpg" ALT=""></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><BR STYLE="clear: both"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; color: #333333"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt; letter-spacing: 2.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Dickinson
Wright PLLC</FONT></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt; letter-spacing: 2.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">September
1, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Page
2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">This
opinion is limited in all respects to matters arising under the Delaware General Corporation Law. Our review of matters arising under
the Delaware General Corporation Law has been limited to a review of the text of the Delaware General Corporation Law as set forth at
8 Del C. chapter 1, which is stated to include all acts effective as of August 31, 2023, in each case without regard to any legislative
history or judicial decisions or any rules, regulations, guidelines, releases or interpretations thereof or any other review of the laws
of the State of Delaware. We assume that such publication accurately sets forth the provisions of the Delaware General Corporation Law
as in effect on the date hereof. We express no opinion with respect to the law of any other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">We
hereby consent to the use of this opinion as Exhibit 5.1 to the Company&rsquo;s Current Report on Form 8-K filed with the SEC on the
date hereof, which is incorporated by reference into the Registration Statement, and further consent to the reference to us in the Registration
Statement and any amendments thereto. In giving such consent, we do not hereby admit that we are within the category of persons whose
consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white; color: #333333"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">This
opinion is intended solely for use in connection with the offer and sale of the Placement Shares pursuant to the Registration Statement
and is not to be relied upon for any other purpose or delivered to or relied upon by any other person without our prior written consent.
This opinion is rendered as of the date hereof and based solely on our understanding of facts in existence as of such date after the
examination described in this opinion. We assume no obligation to advise you of any fact, circumstance, event or change in the law or
the facts that may hereafter be brought to our attention whether or not such occurrence would affect or modify the opinions expressed
herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Very
                                            truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"> /s/
                                            Dickinson Wright PLLC </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding: 0pt; font: 10pt Times New Roman, Times, Serif">Dickinson Wright PLLC</TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex5-1_004.jpg" ALT="">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 161.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex5-1_001.jpg
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  U 1 # 2(  A$! Q$!_\0
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MX2 1.@&X'H5()!'XU<JI9'4&,K7R6T?(\M('9\#'.20._M5N@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** .1^(5J;K2M)S_JX]9LGDX_A\T#^9
M%==5'5[ :GI4]IG#, R'T=2&4_@P!JXA+1JS+M8@$KZ&@!U%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex5-1_002.jpg
<TEXT>
begin 644 ex5-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !" IX# 2(  A$! Q$!_\0
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MW_V0O^CCOA'_ .%EI/\ \?H ^IJ*^6?^&W_V0O\ HX[X1_\ A9:3_P#'Z/\
MAM_]D+_HX[X1_P#A9:3_ /'Z /J:BOEG_AM_]D+_ *..^$?_ (66D_\ Q^C_
M (;?_9"_Z..^$?\ X66D_P#Q^@#ZFHKY9_X;?_9"_P"CCOA'_P"%EI/_ ,?H
M_P"&W_V0O^CCOA'_ .%EI/\ \?H ^IJ*^6?^&W_V0O\ HX[X1_\ A9:3_P#'
MZ/\ AM_]D+_HX[X1_P#A9:3_ /'Z /J:BOEG_AM_]D+_ *..^$?_ (66D_\
MQ^C_ (;?_9"_Z..^$?\ X66D_P#Q^@#ZFHKY9_X;?_9"_P"CCOA'_P"%EI/_
M ,?H_P"&W_V0O^CCOA'_ .%EI/\ \?H ^IJ*^6?^&W_V0O\ HX[X1_\ A9:3
M_P#'Z/\ AM_]D+_HX[X1_P#A9:3_ /'Z /J:BOEG_AM_]D+_ *..^$?_ (66
MD_\ Q^C_ (;?_9"_Z..^$?\ X66D_P#Q^@#ZFHKY9_X;?_9"_P"CCOA'_P"%
MEI/_ ,?H_P"&W_V0O^CCOA'_ .%EI/\ \?H ^IJ*^6?^&W_V0O\ HX[X1_\
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MCOA'_P"%EI/_ ,?H_P"&W_V0O^CCOA'_ .%EI/\ \?H ^IJ*^6?^&W_V0O\
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MFHKY9_X;?_9"_P"CCOA'_P"%EI/_ ,?H_P"&W_V0O^CCOA'_ .%EI/\ \?H
M^IJ*^6?^&W_V0O\ HX[X1_\ A9:3_P#'Z/\ AM_]D+_HX[X1_P#A9:3_ /'Z
M /J:BOEG_AM_]D+_ *..^$?_ (66D_\ Q^C_ (;?_9"_Z..^$?\ X66D_P#Q
M^@#ZFHKY9_X;?_9"_P"CCOA'_P"%EI/_ ,?H_P"&W_V0O^CCOA'_ .%EI/\
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MPUM9K.V\??&_Q*=6EA%UX+^&]YK_ (,T_7=/TLS:Y>7_ (PT6VTZUD\Z:6
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M7%\1Y-,U#PUJVLZ_9>']%TB_GFU[5K:'3[FX3T3XE?\ !0N3X-_L\_$?XO\
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M^(7PC\;?$;PYX*U/X2ZG\#--^#_B'QG\._$7B.VT?Q38:EK.L>%/C+X=\5^
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M/\0(?#?C31K+X)V^F:9%I^H75UHUEJ/P]MO!6L+X?F>VFOY]06/4T\N\9_\
M!+?]F7Q]\"_%'[/WB2X^)5SX0\1_#KX&_#FSUN#Q1I]KXX\&Q_L[IXEA^'?B
M[P5XC7PZ#I/C0P>*]:L?$.K7%G?V/B'2[NZTB^TPZ/J.JZ??_I+10!\(7'[
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M_%GC"R^$U_\  [PQXB\1>"/!WPY\'^$[O6/"?PUUOQ1H^CZG;Z1;7<E_XO\
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M'L_#WA'P;X>T7PIX6T#3T,5AH?ASP[IUMH^B:/8QLSM'9Z;IEG:V5JC.S)!
MBEF()/0T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
@0 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex5-1_004.jpg
<TEXT>
begin 644 ex5-1_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  Z IX# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-E?6-[;/+;7=G=VTD=Q:W5O+)!/!(DL3O&ZL;E 7?<^4?^&7]>_Z.P_:N_\
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M397,,[@7?<\ _P"&7]>_Z.P_:N_\++X;?_.FH_X9?U[_ *.P_:N_\++X;?\
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M)IGB#Q#I]ZEQ;6>M:/=W$+0"2&VU;3)Y%6*_M7E]#TGXE?#G7[;PU>:%X_\
M!6M6GC/5M=T'P==:3XJT+4;;Q9KOA=-;D\2Z+X:GL[^:+7M6\.Q^&?$;Z[IV
MEM=7FDIX?UMM0AMQI-^;<"[/!_\ AE_7O^CL/VKO_"R^&W_SIJ/^&7]>_P"C
ML/VKO_"R^&W_ ,Z:O6M#^.GP1\3ZSJOASPU\8_A7XA\0Z%XOC^'NN:%H?Q"\
M):MK.C>/I;/6-1B\#ZKI=AJ]Q?:=XOET_P .^(+^/PU=P0ZT]GH6L72V1@TR
M]>"?P_\ &OX-^+-''B+PK\6OAEXE\/GQA9_#T:[X?\>>%=9T<^/M1ET^#3_
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MQBG*-@"[/(/^&7]>_P"CL/VKO_"R^&W_ ,Z:C_AE_7O^CL/VKO\ PLOAM_\
M.FKZNK'UOQ#H'AFUM;[Q'KFC^'[*]UC0O#UG>:WJ=EI5K=Z_XHUBQ\.^&=#M
M;B_GMX;C6/$7B#4]-T+0M,B=[W5]8U"QTS3X+B]NX() +ON?-/\ PR_KW_1V
M'[5W_A9?#;_YTU'_  R_KW_1V'[5W_A9?#;_ .=-7O=K\1_AY>W-K96?CSP9
M=WE[XC\2>#K.UMO%&ASW-YXN\&V^HW?B_P +6L$5\\L_B/PK:Z/JUSXDT.)7
MU/0[?2]1FU.UM8[&Y:+%U'XU?!O2/"OA#QUJWQ:^&6E^"/B#>Z'IO@+QCJ/C
MSPK9>%?&^H^)T,GAJP\(>(;G58M(\2WOB&,&30[71KR]GU9 7L([A1F@+L\>
M_P"&7]>_Z.P_:N_\++X;?_.FH_X9?U[_ *.P_:N_\++X;?\ SIJ]UE^)_P -
M(+(ZE/\ $/P-!IP\3:[X*-_-XMT"*R'C+PO'K,WB;PD;I]06 >)O#L/ASQ#+
MKN@E_P"U=(CT'67U"TMUTN^,#+7XJ?#"^M;R^LOB/X#O++3M3\'Z+J%Y:^+_
M  ]<6MCK'Q#CT"7P!I-Y<0ZB\-KJ7CF+Q7X7D\'6$[I=>)H_$F@/HL5\NL:<
M;D"[/#?^&7]>_P"CL/VKO_"R^&W_ ,Z:C_AE_7O^CL/VKO\ PLOAM_\ .FKT
MCQ1^T;^SUX(UWQ1X7\9_'CX,^$/$W@;0K?Q3XV\.^*/BAX(T#7?!_AB[DTV&
MU\1>*=(U77+34/#^@W,VM:-%;ZOJUO::?-)JVF1QW#-?VHER+#]JW]EW5O"T
M'CG2OVD_@%J7@FZ\81?#RU\86'QB^'=YX6N?']Q96>I6_@:#Q#;>(I=)F\83
MZ=J&GW\/AF.[;6I+*^L[I+%H+F"1P+O^O^&.._X9?U[_ *.P_:N_\++X;?\
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M[-%HMCHFM-9:G=ZM+'IMO:R7DBPD"[_K_ACR?_AE_7O^CL/VKO\ PLOAM_\
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M>>,[2#4M,UKXF67B"W^)DNJ+9:QXTU#0_P"B$#'XXS]1WQVHQQ[^N._KC]:
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MB!?1:K-^S3X5\%6GP?N?^"CNN_&;Q#XQ^%GQ'^&OQ*NOB_J6O:?\+==M/B=
M?'UGI_B7PYJFD+!X2M6\50PZ++_1ESZ^G\^?SZ>U% [_ *?@?A#\-/V5?VO)
M[GP#J7QS^'^D^)_'GA[_ (*U:-\:?&GC;2M2\ QZ3XV^"/@;]BN']G[3_P!H
M>+1UU\OH?_"Q]?\ #FB:[K?PZM;;_A*?"WB7Q!J.FV?A^?P[I$&M2\\O[&_[
M5OBCP;X<_9L\/^$->^#&J?!;XI_\%0OB;X8_:GN_$_@/_A -1N_VP=$_:\T7
MX#:A\,-/\(^,]:^+,/B?PW-^U-H/B/Q8?$O@#P=;>%;SX:^*;&PU#67U#PC=
MZ[^_]% 79^#/QO\ V9OC%^TU^SE^SK^SY\(OV7OB-_P3UUCX7_$WP7H_B'Q5
MX<U#]G.]T/X>^$;;]F/]I3X<7>H_#'5OAU\6-5\1^+/A_P"%_%/C#1/"LE^-
M-^&OQ2O/#/Q!_M_P1#X-\7IJ^N^"?8_@C^RSXMU+]K#]G7XW^*OV;XO@#X#\
M/_LLKJ/COX-Z!K_PZN_A/\./VQ?A$=)^ /PGUGPIHO@_59GU5M$_9N\9?&'P
M1\.?%.G:;;:#-\)H? EOXFT;PQXQ\,>%=$T']@_\_P"?SHH"_P"OX_U\@K\Z
M_P#@IE^S1XY_:X^"'@/X'^"H+NW77_C;X4UOQ!XRLK[2[.X^%</@[PKX[\5>
M!_BO"FHZCI]Q?77@'XQ:3\,M=TVRT6+5=7;58+&X32KBQMK^6W_12B@5[:G\
MR+?L(?MS?$'5O$GQ)USP-=_"7X]_M2Z]\&/CK\4?'>C>._ ^MV?[/'QGU;X$
M_P#!1GX1'2=)U;3_ !3_ &UX@@_92\-?$7]E3P?9:QX:M=37Q$;2WU;PA/JX
MM/$$FD?6GB+X(_&/XG_##]C/X8_"C]D?QO\ L/ZQ^SI^T;\ M8\5ZWI;?LK^
M(_#'A?P=X2^#WQY\+Z]K?PLDTOX@^.(?'OA/P?K^OZ?IEG-XX\">'_%6HV7Q
M$L/$&G^"QK2>+H?#/[=4>GM_@:!W?E_6GY'\U^M?L"?M<WUUX\M=4\ S_%"T
MN-7_ &OM6\42>+O$7PF\*VW[1O@;QC_P4;_94_: E^$VMVGAO48-!T%/VH?@
M#\,OB1X9EMM1\/:3X)MX=0?P]\2U\-V.L75I/Z[\8?@#^V5^VKH'CK]FSQ-\
M#O#?P._9<^)'QCT;6I)_BC\/_A=:W.E_!KP9\(_$%Q;^!?'W@?X _M.ZCJ'C
M?6K#XXW'PEF^&?B/0O&'A/[-9_#35=7UZTCTNPT.Q\1_OF>?\_Y_&B@+O^NG
MFM3^8OXN_L8_\% ?BKX.^,'QSF^$PB_:?\:?L?\ [*?[./Q*\(7_ (Y^&XTO
MX^:/'9_%[PC^TGH>FZQ!XQFT#0]4\ ^.-0^'_P"TO\+]>UQM*DU&*QO_ (86
M6I6UO\1?'*:?_3I110*]SXR_X*%_"'Q)\>_V-/CO\'/"?@J#XC:S\0O#6E>'
MU\#75UHMG:>*=,G\6^'IO$&C7D_B'4M(T<6=YX?AU1+N.]U*U2>V$MO&[3RQ
M1O\ C?XU_8Y_;@\ _'>QUJP\$_$OXC>!O@E\>/@!IWP@^,GPVU']GOQS\6O%
M/[.?@G]D7_@I;\-?#^IZ_P"#_P!H3QUH'A[Q#\0OA9JW[37PL^!?Q!U3QP3J
MOQ!L(3\9](74M:U'Q#)H7]+M% T[?C^*L?A7\6?V=OVK;3]H#Q1\1OA9\'=6
M\4_#:Y\"V/[>'A70_$&O_"G1-1U'_@HCX._9N\1?LJ^"_@KXS\)GQBWAZRL=
M6T[7_A[\<M9\5Z/+/X#\-_$'X.+>Z9KU[J=S8?VCY+\*/V-/VI/V0KKX'_#N
MY^#<G[1_PJ^ G[7'@7]HW1=;^!=MX!\)1ZAI/Q(_87_:"_9^^-&E6/@3XW_'
MF._E\4VG[04&A?&SX@Z_?>*+*U\7ZW^TQK6N^&M,0Z!XDTS1OZ+J* NS^;7X
MD?L$_MI>.?AUH?A;X:_#_P !_!JU^$WB[]J_]N7X*_#_ ,3S^'_%?ACP#^TE
M\0_CQ?\ Q#_9;^$7@=? ?Q.\*:1X/^(WP_TO2O%'BKXB>,93XN^!_A/Q3\>]
M?\+^$D^)GA[2WUI/Z+_#6IZCK7AS0-8U?0;[PKJVK:+I6IZIX7U2YTZ\U+PW
MJ-_8P75[H&HWFCW5]I-W?:/<RRZ==W.EWUYIT]Q;22V5W<VSQ3/M8_H/RS_C
M_*EH!N_X_B?/7[6OPR\:_&G]ES]HCX0_#?7X?"_C_P")WP6^)?@7P;K]U=W6
MG6>G>)/%'A'5M&TB2^U*PAN+_2[&6]O(;>]U33[:YO\ 3;26:^LK>>ZMXH7_
M ![^,_[+/[07Q\^)GP@^(GPA_9;\2?L9Z'\.[S]C/X=Z[HAO_P!FJX\3S6OP
MI_:=\+?$O_A,M$\/>#_&OCOX:ZG\/?V4_ FD>,K'X=R:S))KGB*;XL^+-.\+
M?#G^S;('5_Z":,4"NUT_K;[S^:?XK?\ !/G]L7Q5K7Q-T\Z!>_%*37/C+^V1
MXLO?&7C#6/A+X)L?C/X \?\ PK_8NLM-\ >+-.\&7MA9^'/#O[1>E?"/XG_L
M]:W/9>$8I='T2]U#7?%^CVFFZA!>ZI^I_P"SC\/O&NJ_M4_&;]HZY^ VO_LQ
M^!/%GP+^"OP=M_ /BV?X5IXR^(_B[X<>*?BCKTWCWQ'H_P '/'/Q#\(Z=I/@
MGPUXST;P#X)O[WQ-/XEU>WF\26UQINF>%]!\(W.L_H310._D@ZU^9O[6G[//
MQ#^)/QYOO&G@WX=6OB'1[G_@GA^VY\&QKPN_"=A(_P 6_BEK_P"SU-\-_"[M
MJFJV&L)>^(=-\&^*A:ZZL T/1[?2YX-7UK2FOK"*]_3*B@6Q_/+X;_8[_:<^
M,G@O]AVQ\0^%/BY\*_B5^R]I/Q2U;PK\4?BKI?[-_AG4?@W\9M)^"OP;TSX1
MZQ8:#^SQX^\1Z=X^^%>K>)] \6_#GQG878F\1^./ASK'Q \&>+$LO#NMZ/JL
M_P OZE_P3X_;LUCX%?&;XA:1\"+3P9^TAJW[$-K\%$^%$WQ$^'6IZ'\2M*^-
M/[2O_!2;Q1^T;^SY8>+H/&4N@V,OA?1?C3^S?\=OA_XWUU-*L]6\7^"O!'A!
M_$&E6.N?%:PTK^KK'7W.?T _I10.[OT]/Q^X_"/P9^SK\5;CPG^W-\'?C9\"
M_P!J+Q%\//B#\</VBOBGX%TGX;6_[&VE:?JUMXJ_:XE^+GPU\7?";Q_J_P 5
M+#QSJWCF.VO]%^)4OA'X[V%CX%6/P_KOA/5-%U6.+2/!^O;7P]^%G[9.G_%;
M]F[XM7GP=\<67QVUJX\/^ /VA_&7B>V_993X%^)OV4?!_P"T#\8]<\$S?%O0
M?"?CF_\ &WP__;*\-_"KQS/\2KE_V6-!?X*:O\>O'%_X=U:[\0?#:VCN/ 7[
MA44!?R7]*W_!/YC/AS^SK^VOX<_9$_X)Z?#[4?@I^T[IWC[]DKXM? _4/&NG
M6G@S_@GU?ZQX-\->'_V$/VH/@/X@?X/V]Q\7IO _Q7\/^'_B!XQ\)>&[W7/B
M[J$?CV?2/%=EXOT>SU*_LM:N-)_I(\"2ZA/X(\'S:M8:UI>JR>&-!?4M-\1V
MGARP\06.H-I=K]LM-<L?!]]J?A*SU>"X\R/4;3PQJ-_X?MKM98='N[C3TMY6
MZNB@&[_C^)#<6UM>0M;W=O!=6[E"\%Q%'/"YC=9(RT4JLC%)$21"5.UU5UPR
M@C^?#P#^S1^U%\&_ W_!'][/X,_%?3]6_9^_8"U3X&?M":=\(-'_ &3O'.N>
M#_B5JMA^Q3Y_@_Q3;?&/XAZ/X;N])U*3X0^.X-5\<_"R_P#$VKV\OAV-+'5/
ML^LV<U]_0K10*Y_/]XL_9E_:^\/_ !:_;4^*GPC^! TN^_:^\*?%[X3? D_\
M)SX/5_V.=7\2?$'X<?#[XB_&R^TRX\?6VE_V;^V!9V@_;$\<Z5\,((M>AU/X
M ^!?#GCNUN/BKXO:2VY>']CK]I_X"?"_3OAW\+_@KK/B'XN?LT?%KX[:?^PS
MX_\ @]IWP/TO]F2'X,_M >&_A?\ $G7OA?\ '+X6_'_XW>(O'>A?!"\^*\OB
M?X=>(KOP?-XF^-OA+PQ\,[/7/AKXGL+;Q#::%XD_HIHH'=^73IV_K\?F-3>4
M0R!1)M7S C%D#X&X(S*K,H;(5BJDC!*@\#Y;_;8^%OBCXP_LN?%[P?X L&U3
MXGZ?HFE_$CX/Z<EY8:<;WXU_!GQ-HGQA^#%J=2U2YLM.TQ)_BEX%\(QR:E>7
MMG;V$;/=RW5ND)F3ZFHH$?S->&/V"OVW/"<'Q@?0O 5EIOB/XF?!#4/%_A_7
MIO&GAN_MO!_[8W_!2R]^"_@']N/Q=)IUOXJLUBT[]E#2_@MXQ^*FEZGHURE[
MXPL/C[XA\._#^_\ $NJ2WUEIOI,'[(W[47P.^&&@?#[X<?!'6?$7Q@_9@^+W
M[0V@_L4_$#X5VGP-T[]E^\^!GQ^MOA+\8;SX;?&WX6?';XS>(O'_ (/^ <'C
M_5M;^",S^ Y_$GQR\%>%/@ /$'P\UO3]-\4>'_#OC7^ARB@=WY?\-_P-#^>3
MQ/\ L-_M?7NAZK<V\WBW5="N_P#@HW^W5\9K'X%O#\!;3P]IGPY^+7A7]L/3
MOA]\5X/&BSVWC.[D\7ZE\2?!KQ>'M0\7SZKI;>-3#K?A;2K'1[TZ-R&A?L"_
MM7>$]3\.?$7PI\-GM-5\5_M-?\$N?#_Q_P#A_J'B_P $1P^*_P!GK]FGP;_P
M3W\53_&#19;;Q-=:1-XX_9G^,/P4^-7AB+0[N[M+[QA\.?&WQ5F\/6?B34K?
MX7#5?Z2J* YGY?TOZ9^+O[(_PO\ VK/@]XP_9W^"VN_LZ:5IG@[PO=_&N/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
=HH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>envb-20230901.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaCN+bP9z5Z8uekhvWBwbYlKPycilj3BPy1nSV1W0QgE -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:envb="http://enveric.com/20230901" elementFormDefault="qualified" targetNamespace="http://enveric.com/20230901">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://enveric.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="envb-20230901_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="envb-20230901_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>envb-20230901_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>envb-20230901_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://enveric.com/role/Cover" xlink:href="envb-20230901.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140354992621104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep.  01,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Enveric
Biosciences, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000890821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-4484725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Enveric
Biosciences, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">4851
Tamiami Trail N<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Naples<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">34103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(239)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">302-1707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ENVB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="envb-20230901.xsd" xlink:type="simple"/>
    <context id="AsOf2023-09-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-01</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="AsOf2023-09-01">0000890821</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="AsOf2023-09-01">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="AsOf2023-09-01">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2023-09-01">2023-09-01</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2023-09-01">Enveric Biosciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2023-09-01">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2023-09-01">001-38286</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2023-09-01">95-4484725</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2023-09-01">Enveric Biosciences, Inc.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2023-09-01">4851 Tamiami Trail N</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="AsOf2023-09-01">Suite 200</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="AsOf2023-09-01">Naples</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2023-09-01">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2023-09-01">34103</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2023-09-01">(239)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2023-09-01">302-1707</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2023-09-01">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2023-09-01">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2023-09-01">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2023-09-01">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2023-09-01">Common     stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2023-09-01">ENVB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2023-09-01">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2023-09-01">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M'&X'=P(<7RMEWP;N?4#Y.F?T#U!+ P04    " !3BR%7GZ ;\+$"  #B#
M#0   'AL+W-T>6QE<RYX;6S=5VUKVS 0_BM"/V!N8FKBD1BV0&&PC4+S85^5
M6'8$>O%DN7/ZZZ>S;"=I=67=A['-H<G=/;J[1W<GF:Y;=Y+\X<BY([V2NMW0
MHW/-^R1I#T>N6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<
M2PZFTVY#;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ
M?$,78&F? KP(&K <XRBAC05C$C*$[_VX_!DP::U7A90SP24-AF+=,.>XU7=>
M&18/QA<0&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3
M .B<45XH!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*
MQ+^,%F)?A+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*
M6BL>]O[+"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0
M\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7>>9 ]IV03NA1
M.XJRY/K%.?7A'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMH
MD<VWL,\E=,E[7FY'U=;[021>\%G'!QR>(W?#$T<PGX#%$<"P/!@#S"=X87G^
MI_VLT/T$#..VBB(KU&>%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E
M\!>/AG$##RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!
M#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X
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MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
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MBBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @
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MX3]>?P%02P$"% ,4    " !3BR%7!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( %.+(5=1"DZ>[P
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( %.+(5>97)PC$ 8  )PG   3              "  <T!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ 4XLA5^DX6S]W!   VA$  !@
M             ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( %.+(5>?H!OPL0(  .(,   -              "  ;L,  !X;"]S
M='EL97,N>&UL4$L! A0#%     @ 4XLA5Y>*NQS     $P(   L
M     ( !EP\  %]R96QS+RYR96QS4$L! A0#%     @ 4XLA5ZK$(A8S 0
M(@(   \              ( !@!   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   ( %.+(5<D'INBK0   /@!   :              "  > 1  !X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( %.+(5=ED'F2&0$  ,\#
M   3              "  <42  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0   )  D /@(   \4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="form8-k.htm">form8-k.htm</File>
    <File>envb-20230901.xsd</File>
    <File>envb-20230901_lab.xml</File>
    <File>envb-20230901_pre.xml</File>
    <File>ex1-1.htm</File>
    <File>ex5-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form8-k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "envb-20230901_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "envb-20230901_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "envb-20230901.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "envb",
   "nsuri": "http://enveric.com/20230901",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "AsOf2023-09-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://enveric.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "AsOf2023-09-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001493152-23-031526-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-23-031526-xbrl.zip
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MY\C7G=W@WDY;?.-^N3>PVBW_ U!+ P04    " !3BR%7F0+[9$V@  "QNP,
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MPHEG.+2R[<3B@7/8R8'^$58^>5&?)0\>/#B]_^777WU[#]7P\=&/>&Y?GS[
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M.?],[S%6WA^^3/NNS?!]%&[^@,8^LR]%'Z=#/?,CFH7_P'L89N0_7.P]&J]
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M;TD.JMG+D(F)0G]1[667Y+%72GB/N"7<X]*DHKP];\UD]-*\,Y[G70$\?74
M/!T 3X>H2! 5Z91WV6GX'SDZ\3%C(C=Z1>@FBMDQQYBE<SW-)3UHDI=%T,TE
M&;,JR0"*[$'\/=AS+I0HMQUH;V?-RY7HC7J*-: Y/Q:G$#)#JB'<5!*C52(U
MNJ5@#?53@6UP(MZ/&'<<)$H1'3&#[\I<A+\EI*C!GS#3DCIJ-@K.KE*Y-H-
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MUT')O%,N/L*NKM<,">2)P(((1-#3+\<T'3"6!:P;I4]#GS>TN5R4DN^S#$X
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M4N]1UF^7PCUJ*9N5VCPB0&L:P)<-Y WT45.^2PZ(^/9V01'/97DE2T*CDWU
MTW3(2)9>O*&1#.Z8B[D'QG&KE; ^OCA9P:8\G%3TOVOVH1Y._C@9[ -GK11?
MGTX$GNNR*DV;8_0#0+5W"$R-<FQ)OF'B8QA&;^G90->ML2/G&6&/-O ]* !3
M.?>PK ) :.^Q!X/H$Y\2L:)QSLE59H$83[>1)RS>F2A3[O>#RFX@/#CF8*6.
ME)?E,@XF'1^9H!4F<:S9/Q*_<'%^EEH.X]UB3(EDBUW<+$-O]-)X>\YA_;!T
MVN$@?.)30A9D/@>(+ 4EYH(:,4H!0ZH#$I(Z'N18^)S</#B[]Y_ZM\L&*045
M$B!U*S9*0U?5SA/#F-FF6$F&3CMNI0)6DRL*+H]<<AESP>Q:AWN.YQHN64*4
M#31D)1086$_S4P-QE:X\O$9EY:ZKVEI5J<P\BI-4%.KTS<'LJ:$E)-N ERY*
MA[[ H.M+^6X0N_RL9/%S/%YXNI[/-7D1H5E,K[E^Z$],+\O(A19O<#Y5?B:<
M,9'8U) [D-'1H@:9W)G61;@$F"/)1L'.T-,9N8#G4W*<CJ6"T]<Y>2RFR-G
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M8=%"-=1J;R$72SN7<)D:+3A*,8&^83N/M,5!5N_ I"8+EE5IQK:(.&!=-=M
MB=X.9*2&(>**=NV#DX$UVYCB&F%@Y_ J-60W)1Z_,<'G +?L@(?TVAFH!_&[
M Y.:"'..JTSJV38[NJ8.\--8F0PXR$H-IR5@=/4:0;22!6,3"J%DF^4<M"'V
MW692-,JLS=!_X]^:UA6IF 'N1V)L$/^9H)[^3XOM&LW;&9$"K0FKGB:76+?)
M^.0U6V4ZLZ!K,-B,:R&[M0_VOTZER'PI\3W]B>%K&*O#Q(9@G8.T.(R8HML,
M)NNHQ5XA03NF-Z1?($:C=?7?O0=*!:HMY&+Z/XNU[GW+H][-@"+N'VX>ADF?
ML+FJ^LG^0@V?S5T-Q3@T::?(Z9[W%X@;?B(<CO(]BA7@1A01G!LK1;.V([.N
M"%A77<TI@R*4)EF[]7()JWHTX&,@5%^F[I 3I'DU.Z999Q1@PQ^#GSE+]F\
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M 3@CJO%?5, O<LS3%LDS,@"<W/Z^R2]MW<&A7OGN3&HR U'\M4+"+%!95*G
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M8GB,%Q:K*^T4P;G0Q4A+9&^6/6,W@O@K8K!Z@=X"9;95&2N"H7M!"K-17%.
M@#_IVYI8N.2L$3>$;HM2X/D6-MW DUQ#U\&Q!6S&V=(MY5!M>:&X+T>5G98"
MG$:%B4)6%9LI=AEZ$$^B$/O8KI+&>8TNE K6"S9[C!UGB#O^ G;003/HLZA6
M@YQY;M9.X']68OQ*M=/7<9I1GAA(TGA1IGP8 &<X3B=8+4>US .[]A-HC4MQ
M4[)TI'L# /&L\V0\/;+26["-U.=!J([#F^#*-"4E;ETQW_5I+1V&3'CM3$Q
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MLY9F2F<\MOKC=P;!:J6$@N5)5Q-:GAK6%$S8C$-B['!DC*WK-1N!>@[)1+(
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M55<LVAB9%N7J,'EZX4L+^9OECNEAIA01.A<PYT47\W7]/ZNZ5LZNJY6"81<
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M&+A1N*K2&T$3']SGJ *' R- $ %.$V -S.40D94,66O:WO.!93H,$+^*Z5+
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M     &5N=F(M,C R,S Y,#$N>'-D4$L! A0#%     @ 4XLA5RZU(T7]"@
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=."UK+FAT;5!+!08     !@ & &P!  #[V0     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
